APPROV
DRUG PR

WITH
THERAPEUTIC EQUIV

15TH E

U.S. DEPARTMENT OF HEALTH AND HUMAN

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEAR
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCE

CUMULATIVE SUPPLEMENT 8
JAN'95-AUG'95

PPROVED
RUG PRODUCTS

WITH
APEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

ENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
OD AND DRUG ADMINISTRATION
FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
N OF DRUG INFORMATION RESOURCES

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Cumulative Supplement 8

AUGUST 1995

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

CUMULATIVE SUPPLEMENT 8
AUGUST 1995

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 15th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 15th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 16th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required

to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation

of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BOOTS PHARMACEUTICALS INC (BOOTS)	KNOLL PHARMACEUTICAL COMPANY SUB BASF CORPORATION (KNOLL PHARM)
BRIAN PHARMACEUTICALS INC (BRIAN)	HYGENICS PHARMACEUTICALS INC (HYGENICS)
DORSEY LABORATORIES DIV SANDOZ WANDER INC (DORSEY)	SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS CORP (SANDOZ)
MARION MERRELL DOW INC (MARION MERRELL DOW)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
MERRELL DOW PHARMACEUTICALS INC SUB DOW CHEMICAL CO (MERRELL DOW)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
MILES PHARMACEUTICAL DIV MILES INC (MILES)	BAYER CORPORATION (BAYER)
PENNEX PHARMACEUTICALS INC (PENNEX)	MORTON GROVE PHARMACEUTICALS INC (MORTON GROVE)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
TAP PHARMACEUTICALS INC (TAP PHARMS)	TAP HOLDINGS INC (TAP HOLDINGS)

1.4 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1994) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1994	MAR 1995	JUN 1995	SEP 1995
DRUG PRODUCTS LISTED	9141	9195	9221	
SINGLE SOURCE	2178 (23.8%)	2186 (23.8%)	2186 (23.7%)	
MULTISOURCE	6963 (76.2%)	7009 (76.2%)	7035 (76.3%)	
THERAPEUTICALLY EQUIVALENT	6330 (69.2%)	6380 (69.4%)	6399 (69.4%)	
NOT THERAPEUTICALLY EQUIVALENT	453 (5.0%)	453 (4.9%)	452 (4.9%)	
EXCEPTIONS[1]	180 (2.0%)	176 (1.9%)	184 (2.0%)	
NEW MOLECULAR ENTITIES APPROVED	--	2	10	
NUMBER OF APPLICANTS	534	541	559	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

		ACEBUTOLOL HCL		
AB		MYLAN	**EQ 200MG BASE**	**N74288 001** APR 24, 1995
AB			**EQ 400MG BASE**	**N74288 002** APR 24, 1995
		SECTRAL		
AB		WYETH AYERST	**EQ 200MG BASE**	**N18917 001** DEC 28, 1984
AB	+		**EQ 400MG BASE**	**N18917 003** DEC 28, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE		
AB		WEST WARD PHARM	**325MG;50MG;40MG**	**N89718 001** JUN 12, 1995

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE		
AA		BARRE	**120MG/5ML;12MG/5ML**	**N85861 001**
		APAP W/ CODEINE		
AA		BARRE	**120MG/5ML;12MG/5ML**	**N85861 001**

TABLET; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE		
AA		KV PHARM	**300MG;30MG**	**N85288 001**
AA			**300MG;60MG**	**N85365 001**
			325MG;15MG	N85364 001
			325MG;45MG	N85363 001
	@		300MG;30MG	N85288 001
	@		300MG;60MG	N85365 001
	@		325MG;15MG	N85364 001
	@		325MG;45MG	N85363 001
AA		MIKART	**650MG;30MG**	**N89231 001** MAR 03, 1986
	+		650MG;30MG	N89231 001 MAR 03, 1986
	+	ROXANE	500MG;15MG	N89511 001 APR 25, 1989
	+		500MG;30MG	N89512 001 APR 25, 1989

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE		
	+	ROXANE	500MG;60MG	N89513 001 APR 25, 1989
	@		500MG;15MG	N89511 001 APR 25, 1989
	@		500MG;30MG	N89512 001 APR 25, 1989
	@		500MG;60MG	N89513 001 APR 25, 1989
		PHENAPHEN-650 W/ CODEINE		
AA	+	ROBINS AH	**650MG;30MG**	**N85856 001**
	@		650MG;30MG	N85856 001

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		ANEXSIA		
AA		BOEHRINGER MANNHEIM	**500MG;5MG**	**N89160 001** APR 23, 1987
AA		KING PHARMS	**500MG;5MG**	**N89160 001** APR 23, 1987
		ANEXSIA 7.5/650		
AA		BOEHRINGER MANNHEIM	**650MG;7.5MG**	**N89725 001** SEP 30, 1987
AA		KING PHARMS	**650MG;7.5MG**	**N89725 001** SEP 30, 1987
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
AA		HALSEY	**500MG;5MG**	**N89554 001** JUN 12, 1987
	@		500MG;5MG	N89554 001 JUN 12, 1987
AA		KING PHARMS	**500MG;5MG**	**N40084 002** JUN 01, 1995
AA			**750MG;7.5MG**	**N40084 001** JUN 01, 1995

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

		ROXILOX		
AA		ROXANE	**500MG;5MG**	**N40061 001** JUL 03, 1995

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

	OXYCET				
AA	HALSEY	**325MG;5MG**	**N87463 001**	> ADD >	
			DEC 07, 1983	> ADD >	
AA	MALLINCKRODT	**325MG;5MG**	**N87463 001**	> ADD >	
			DEC 07, 1983	> ADD >	
				> ADD >	
				> ADD >	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	ACETAZOLAMIDE SODIUM				
AP	BEDFORD	**EQ 500MG BASE/VIAL**	**N40089 001**		
			FEB 28, 1995		
	DIAMOX				
AP	+ STORZ OPHTHALM	**EQ 500MG BASE/VIAL**	**N09388 001**		
			DEC 05, 1990		

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE				
AN	DUPONT MERCK	**10%**	**N71364 001**		
			MAY 01, 1989		
AN		**20%**	**N71365 001**		
			MAY 01, 1989		
AN	FAULDING	**10%**	**N71364 001**		
			MAY 01, 1989		
AN		**20%**	**N71365 001**		
			MAY 01, 1989		
AN	LUITPOLD	**10%**	**N72489 001**		
			JUL 28, 1995		
AN		**20%**	**N72547 001**		
			JUL 28, 1995		

ADENOSINE

INJECTABLE; INJECTION

	ADENOSCAN				
+	MEDCO RES	3MG/ML	N20059 001		
			MAY 18, 1995		

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM				
AB	CHELSEA LABS	**0.25MG**	**N74456 001**		
			AUG 31, 1995		
AB		**0.5MG**	**N74456 002**		
			AUG 31, 1995		
AB		**1MG**	**N74456 003**		
			AUG 31, 1995		

ALPROSTADIL

INJECTABLE; INJECTION

	CAVERJECT				
	UPJOHN	0.01MG/VIAL	N20379 001		
			JUL 06, 1995		
+		0.02MG/VIAL	N20379 002		
			JUL 06, 1995		

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

	AMANTADINE HCL				
AA	PHARM ASSOC	**50MG/5ML**	**N74509 001**		
			JUL 17, 1995		

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN				
AP	DUPONT MERCK	**EQ 50MG BASE/ML**	**N63350 001**		
			JUL 30, 1993		
AP		**EQ 250MG BASE/ML**	**N63350 002**		
			JUL 30, 1993		
AP	+ ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001**		
			MAY 18, 1992		
AP	+	**EQ 250MG BASE/ML**	**N63275 001**		
			MAY 18, 1992		
	AMIKACIN SULFATE				
AP	ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001**		
			MAY 18, 1992		
AP		**EQ 250MG BASE/ML**	**N63275 001**		
			MAY 18, 1992		
AP	FAULDING	**EQ 50MG BASE/ML**	**N63350 001**		
			JUL 30, 1993		

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN SULFATE				
AP	FAULDING	EQ 250MG BASE/ML	N63350 002	> DLT >	
			JUL 30, 1993	> DLT >	
AP	SANOFI WINTHROP	EQ 250MG BASE/ML	N64098 001	> ADD >	
			JUN 26, 1995	> ADD >	
AP		EQ 250MG BASE/ML	N64099 001	> ADD >	
			JUN 20, 1995	> ADD >	
	AMIKIN				
AP	APOTHECON	EQ 50MG BASE/ML	N62311 001		
AP	+	EQ 50MG BASE/ML	N62311 001		
AP		EQ 250MG BASE/ML	N62311 002		
AP	+	EQ 250MG BASE/ML	N62311 002		
	@	EQ 50MG BASE/ML	N62562 001		
			SEP 20, 1984		
	@	EQ 250MG BASE/ML	N62562 002		
			SEP 20, 1984		
	@ BRISTOL	EQ 50MG BASE/ML	N62562 001		
			SEP 20, 1984		
	@	EQ 250MG BASE/ML	N62562 002	> ADD >	
			SEP 20, 1984	> ADD >	
	AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			> ADD >	
	@ APOTHECON	EQ 5MG BASE/ML	N50618 002	> ADD >	
			NOV 30, 1987		
	@	EQ 10MG BASE/ML	N50618 001		
			NOV 30, 1987		
	@ BRISTOL	EQ 5MG BASE/ML	N50618 002		
			NOV 30, 1987		
	@	EQ 10MG BASE/ML	N50618 001		
			NOV 30, 1987		

AMINOPHYLLINE

INJECTABLE; INJECTION

	AMINOPHYLLINE				
AP	FUJISAWA	25MG/ML	N87200 001		
AP		25MG/ML	N88407 001		
			JAN 25, 1984		
	@	25MG/ML	N87200 001		
	@	25MG/ML	N88407 001		
			JAN 25, 1984		
AP	KING PHARMS	25MG/ML	N86606 001		
	@	25MG/ML	N86606 001		
	AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
> DLT >	ABBOTT	100MG/100ML	N88147 002		
> DLT >			MAY 03, 1983		

AMINOPHYLLINE

INJECTABLE; INJECTION

	AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
	ABBOTT	200MG/100ML	N88147 003		
			MAY 03, 1982		
	+	100MG/100ML	N88147 002		
			MAY 03, 1983		
	+	200MG/100ML	N88147 003		
			MAY 03, 1983		

TABLET; ORAL

	AMINOPHYLLINE				
BD	PHOENIX LABS NY	100MG	N85409 001		
BD		200MG	N85410 001		
	@	100MG	N85409 001		
	@	200MG	N85410 001		

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

	CORDARONE				
	+ WYETH AYERST	50MG/ML	N20377 001		
			AUG 03, 1995		

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	AMITRIPTYLINE HCL				
AB	ROXANE	150MG	N86090 001		
	@	150MG	N86090 001		

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

	LOTREL				
	CIBA GEIGY	EQ 2.5MG BASE;10MG	N20364 002		
			MAR 03, 1995		
		EQ 5MG BASE;10MG	N20364 003		
			MAR 03, 1995		
	+	EQ 5MG BASE;20MG	N20364 004		
			MAR 03, 1995		

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	CONSOLIDATED PHARM	250MG	N62058 001	
AB		500MG	N62058 002	
	COMOX			
AB	COPANOS	250MG	N62058 001	
AB		500MG	N62058 002	
	POLYMOX			
AB	APOTHECON	250MG	N63099 001	MAR 20, 1992
AB		500MG	N63099 002	MAR 20, 1992
	TRIMOX			
AB	APOTHECON	250MG	N63099 001	MAR 20, 1992
AB		500MG	N63099 002	MAR 20, 1992

POWDER FOR RECONSTITUTION; ORAL

	AMOXICILLIN			
AB	CONSOLIDATED PHARM	125MG/5ML	N62059 001	
AB		250MG/5ML	N62059 002	
	AMOXICILLIN TRIHYDRATE			
AB	COPANOS	125MG/5ML	N62059 001	
AB		250MG/5ML	N62059 002	

AMPHOTERICIN B

INJECTABLE; INJECTION

	AMPHOTERICIN B			
AP	GENSIA	50MG/VIAL	N64062 001	MAR 31, 1995

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM			
AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001	
AP		EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002	
AP		EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM			
AP	APOTHECON	EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004	
AP		EQ 1GM BASE/VIAL	N62738 001	FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005	
AP		EQ 2GM BASE/VIAL	N62738 002	FEB 19, 1987
AP		EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988
AP +		EQ 10GM BASE/VIAL	N61395 006	
@	CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	N61936 005	
@		EQ 250MG BASE/VIAL	N61936 001	
@		EQ 500MG BASE/VIAL	N61936 002	
@		EQ 1GM BASE/VIAL	N61936 003	
@		EQ 2GM BASE/VIAL	N61936 004	
@	COPANOS	EQ 125MG BASE/VIAL	N61936 005	
@		EQ 250MG BASE/VIAL	N61936 001	
@		EQ 500MG BASE/VIAL	N61936 002	
@		EQ 1GM BASE/VIAL	N61936 003	
@		EQ 2GM BASE/VIAL	N61936 004	
	PRINCIPEN			
AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001	
AP		EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002	
AP		EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003	
AP		EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004	
AP		EQ 1GM BASE/VIAL	N62738 001	FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005	
AP		EQ 2GM BASE/VIAL	N62738 002	FEB 19, 1987
AP		EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988
AP +		EQ 10GM BASE/VIAL	N61395 006	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

		AMPICILLIN TRIHYDRATE			
> ADD >	AB	BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995
> ADD >					
> ADD >	AB		EQ 500MG BASE	N64082 002	AUG 29, 1995
> ADD >					
	AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
	AB		EQ 500MG BASE	N61602 002	
	AB	COPANOS	EQ 250MG BASE	N61602 001	
	AB		EQ 500MG BASE	N61602 002	

POWDER FOR RECONSTITUTION; ORAL

		AMPICILLIN TRIHYDRATE			
	AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
	AB		EQ 250MG BASE/5ML	N61601 002	
	AB	COPANOS	EQ 125MG BASE/5ML	N61601 001	
	AB		EQ 250MG BASE/5ML	N61601 002	
		POLYCILLIN			
	AB	+ BRISTOL	EQ 500MG BASE/5ML	N50308 003	
		+	EQ 500MG BASE/5ML	N50308 003	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		VASOCON-A			
		+ CIBA VISION	0.5%;0.05%	N18746 001	APR 30, 1990

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

		BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE			
> ADD >	AB	WATSON LABS	325MG;50MG;40MG;30MG	N74359 001	AUG 31, 1995
> ADD >					
		FIORINAL W/CODEINE NO 3			
> ADD >	AB	+ SANDOZ	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990
> ADD >					

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

		METHOCARBAMOL AND ASPIRIN			
	AB	STEVENS J	325MG;400MG	N81145 001	JAN 31, 1995

ATENOLOL

TABLET; ORAL

		ATENOLOL			
	AB	COPLEY PHARM	50MG	N74120 001	FEB 24, 1995
	AB		100MG	N74120 002	FEB 24, 1995
	AB	LEMMON	50MG	N74056 001	JAN 18, 1995
	AB		100MG	N74056 002	JAN 18, 1995
	AB	MARTEC	50MG	N74127 001	FEB 21, 1995
	AB		100MG	N74127 002	FEB 21, 1995

ATOVAQUONE

SUSPENSION; ORAL

		MEPRON			
		+ BURROUGHS WELLCOME	750MG/5ML	N20500 001	FEB 08, 1995

ATROPINE

INJECTABLE; INJECTION

		ATROPEN			
> DLT >	AP	+ SURVIVAL TECH	EQ 2MG SULFATE/0.7ML	N17106 001	
> ADD >		+	EQ 2MG SULFATE/0.7ML	N17106 001	
> DLT >		**ATROPINE**			
> DLT >	AP	KALI DUPHAR	EQ 2MG SULFATE/0.7ML	N71295 001	JAN 30, 1987
> DLT >					
> ADD >		@ SOLVAY	EQ 2MG SULFATE/0.7ML	N71295 001	JAN 30, 1987
> ADD >					

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

		AZATHIOPRINE SODIUM			
	AP	BEDFORD	EQ 100MG BASE/VIAL	N74419 001	MAR 31, 1995
		IMURAN			
	AP	+ BURROUGHS WELLCOME	EQ 100MG BASE/VIAL	N17391 001	

BACITRACIN

INJECTABLE; INJECTION

		BACITRACIN			
AP	+	**PFIZER**	**50,000 UNITS/VIAL**	**N60282 001**	> ADD >
	@		50,000 UNITS/VIAL	N60282 001	> ADD >
AP		**UPJOHN**	**50,000 UNITS/VIAL**	**N60733 002**	> ADD >
	+		50,000 UNITS/VIAL	N60733 002	> ADD >
					> ADD >

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		BACITRACIN ZINC AND POLYMYXIN B SULFATE		
AT		ADV REMEDIES	**500 UNITS/GM; 10,000 UNITS/GM**	**N64028 001** JAN 30, 1995
AT		BAUSCH AND LOMB	**500 UNITS/GM; 10,000 UNITS/GM**	**N64046 001** JAN 26, 1995
		POLYSPORIN		
AT	+	BURROUGHS WELLCOME	**500 UNITS/GM; 10,000 UNITS/GM**	**N61229 001**

BENDROFLUMETHIAZIDE

TABLET; ORAL

	NATURETIN-10		
+	APOTHECON	10MG	N12164 003
+	SQUIBB	10MG	N12164 003
	NATURETIN-2.5		
@	APOTHECON	2.5MG	N12164 001
@	SQUIBB	2.5MG	N12164 001
	NATURETIN-5		
	APOTHECON	5MG	N12164 002
	SQUIBB	5MG	N12164 002

BENTONITE; SULFUR

POWDER; TOPICAL

	BENSULFOID		
@	POYTHRESS	66.64%;33.32%	N02918 001

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL

		BETAMETHASONE DIPROPIONATE		
AB		NMC	**EQ 0.05% BASE**	**N74304 001** AUG 31, 1995
		DIPROLENE		
AB	+	SCHERING	**EQ 0.05% BASE**	**N18741 001** JUL 27, 1983

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLOL		
AP	DUPONT MERCK	**50MG/ML**	**N17954 001**
AP	FAULDING	**50MG/ML**	**N17954 001**

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

	DIMETANE-DC		
AA	ROBINS AH	**2MG/5ML;10MG/5ML; 12.5MG/5ML**	**N11694 006** MAR 29, 1984
AA	+	**2MG/5ML;10MG/5ML; 12.5MG/5ML**	**N11694 006** MAR 29, 1984

BUMETANIDE

INJECTABLE; INJECTION

	BUMETANIDE		
AP	BEDFORD	**0.25MG/ML**	**N74441 001** JAN 27, 1995

TABLET; ORAL

	BUMETANIDE		
AB	ZENITH LABS	**0.5MG**	**N74225 001** APR 24, 1995
AB		**1MG**	**N74225 002** APR 24, 1995
AB		**2MG**	**N74225 003** APR 24, 1995
	BUMEX		
AB	ROCHE	**0.5MG**	**N18225 002** FEB 28, 1983

BUMETANIDE

TABLET; ORAL

		BUMEX			
AB		ROCHE	1MG	N18225 001 FEB 28, 1983	
AB	+		2MG	N18225 003 JUN 14, 1985	

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		MARCAINE HCL			
AP	+	SANOFI WINTHROP	0.25%	N16964 001	>ADD>
AP	+		0.5%	N16964 006	>ADD>
AP	+		0.75%	N16964 009	>ADD>
AP	+	STERLING WINTHROP	0.25%	N16964 001	>ADD>
AP	+		0.5%	N16964 006	
AP	+		0.75%	N16964 009	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

		MARCAINE HCL W/ EPINEPHRINE			
AP	+	SANOFI WINTHROP	0.25%;0.0091MG/ML	N16964 004	
AP	+		0.5%;0.0091MG/ML	N16964 008	
AP	+		0.75%;0.0091MG/ML	N16964 010	
AP	+	STERLING WINTHROP	0.25%;0.0091MG/ML	N16964 004	
AP	+		0.5%;0.0091MG/ML	N16964 008	
AP	+		0.75%;0.0091MG/ML	N16964 010	

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

		CAFERGOT		
AA	+	SANDOZ	100MG;1MG	N06620 001
	@		100MG;1MG	N06620 001
		ERCATAB		
AA		GENEVA PHARMS	100MG;1MG	N84294 001
AA	+		100MG;1MG	N84294 001

CALCITONIN, SALMON

INJECTABLE; INJECTION

		CALCITONIN-SALMON		
AP		ASTRA	200 IU/ML	N73690 001 APR 14, 1995

SPRAY, METERED; NASAL

		MIACALCIN		
	+	SANDOZ	200 IU/INH	N20313 002 AUG 17, 1995

CAPTOPRIL

TABLET; ORAL

		CAPOTEN		
AB		BRISTOL MYERS SQUIBB	12.5MG	N18343 005 JAN 17, 1985
AB			25MG	N18343 002
AB			50MG	N18343 001
AB	+		100MG	N18343 003
		CAPTOPRIL		
AB		APOTHECON	12.5MG	N74472 001 MAR 31, 1995
AB			25MG	N74472 002 MAR 31, 1995
AB			50MG	N74472 003 MAR 31, 1995
AB			100MG	N74472 004 MAR 31, 1995

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		CAPOZIDE 25/25		
		SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984
	+		25MG;25MG	N18709 002 OCT 12, 1984
		CAPOZIDE 50/15		
		SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984
	+		50MG;15MG	N18709 004 OCT 12, 1984
		CAPOZIDE 50/25		
	+	SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPOZIDE 50/25

		SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984

CARBACHOL

SOLUTION; INTRAOCULAR
CARBASTAT

AT		CIBA	0.01%	N73677 001 APR 28, 1995

MIOSTAT

AT	+	ALCON	0.01%	N16968 001

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

AB		GENEVA PHARMS	10MG;100MG	N73586 001 JUN 29, 1995
AB			25MG;100MG	N73587 001 JUN 29, 1995
AB			25MG;250MG	N73620 001 JUN 29, 1995

CEFACLOR

CAPSULE; ORAL
CECLOR

AB	+	LILLY	EQ 250MG BASE	N50521 001
AB			EQ 250MG BASE	N62205 001
AB	+		EQ 500MG BASE	N50521 002
AB			EQ 500MG BASE	N62205 002

CEFACLOR

AB		LEDERLE	EQ 250MG BASE	N64107 001 APR 27, 1995
AB			EQ 500MG BASE	N64107 002 APR 27, 1995
AB		ZENITH LABS	EQ 250MG BASE	N64061 001 APR 27, 1995
AB			EQ 500MG BASE	N64061 002 APR 27, 1995

POWDER FOR RECONSTITUTION; ORAL
CECLOR

AB	+	LILLY	EQ 125MG BASE/5ML	N50522 001

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL
CECLOR

AB		LILLY	EQ 125MG BASE/5ML	N62206 001
AB	+		EQ 187MG BASE/5ML	N62206 003 APR 20, 1988
AB	+		EQ 250MG BASE/5ML	N50522 002
AB			EQ 250MG BASE/5ML	N62206 002
AB	+		EQ 375MG BASE/5ML	N62206 004 APR 20, 1988

CEFACLOR

AB		LEDERLE	EQ 125MG BASE/5ML	N64114 001 APR 28, 1995
AB			EQ 187MG BASE/5ML	N64115 001 APR 28, 1995
AB			EQ 250MG BASE/5ML	N64116 001 APR 28, 1995
AB			EQ 375MG BASE/5ML	N64110 001 APR 28, 1995
AB		ZENITH LABS	EQ 125MG BASE/5ML	N64087 001 APR 28, 1995
AB			EQ 187MG BASE/5ML	N64086 001 APR 28, 1995
AB			EQ 250MG BASE/5ML	N64085 001 APR 28, 1995
AB			EQ 375MG BASE/5ML	N64070 001 APR 28, 1995

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL

	*	LILLY	EQ 500MG BASE/VIAL	N50504 001
	@		EQ 500MG BASE/VIAL	N50504 001

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP		APOTHECON	EQ 500MG BASE/VIAL	N62831 001 DEC 09, 1988
AP			EQ 1GM BASE/VIAL	N62831 002 DEC 09, 1988
AP			EQ 10GM BASE/VIAL	N62831 003 SEP 25, 1992

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	ELKINS SINN	EQ 250MG BASE/VIAL	N62807 001	JAN 12, 1988
AP		EQ 500MG BASE/VIAL	N62807 002	JAN 12, 1988
AP		EQ 1GM BASE/VIAL	N62807 003	JAN 12, 1988
AP		EQ 5GM BASE/VIAL	N62807 004	JAN 12, 1988
AP		EQ 10GM BASE/VIAL	N62807 005	JAN 12, 1988
AP		EQ 20GM BASE/VIAL	N62807 006	JAN 12, 1988
	@	EQ 250MG BASE/VIAL	N62807 001	JAN 12, 1988
	@	EQ 500MG BASE/VIAL	N62807 002	JAN 12, 1988
	@	EQ 1GM BASE/VIAL	N62807 003	JAN 12, 1988
	@	EQ 5GM BASE/VIAL	N62807 004	JAN 12, 1988
	@	EQ 10GM BASE/VIAL	N62807 005	JAN 12, 1988
	@	EQ 20GM BASE/VIAL	N62807 006	JAN 12, 1988
	ZOLICEF			
AP	APOTHECON	EQ 500MG BASE/VIAL	N62831 001	DEC 09, 1988
AP		EQ 1GM BASE/VIAL	N62831 002	DEC 09, 1988
AP		EQ 10GM BASE/VIAL	N62831 003	SEP 25, 1992

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID			
PFIZER	EQ 1GM BASE/VIAL	N63333 001	MAR 31, 1995
	EQ 2GM BASE/VIAL	N63333 002	MAR 31, 1995

CEFORANIDE

INJECTABLE; INJECTION

PRECEF			
APOTHECON	500MG/VIAL	N62579 001	NOV 26, 1984
	1GM/VIAL	N62579 002	NOV 26, 1984
	2GM/VIAL	N62579 003	NOV 26, 1984
	10GM/VIAL	N62579 004	NOV 26, 1984
	20GM/VIAL	N62579 005	NOV 26, 1984
BRISTOL	500MG/VIAL	N62579 001	NOV 26, 1984
	1GM/VIAL	N62579 002	NOV 26, 1984
	2GM/VIAL	N62579 003	NOV 26, 1984
	10GM/VIAL	N62579 004	NOV 26, 1984
	20GM/VIAL	N62579 005	NOV 26, 1984

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+ MERCK SHARP DOHME	EQ 20MG BASE/ML	N50581 002	SEP 20, 1984
	+	EQ 40MG BASE/ML	N50581 001	SEP 20, 1984
	@	EQ 20MG BASE/ML	N50581 002	SEP 20, 1984
	@	EQ 40MG BASE/ML	N50581 001	SEP 20, 1984

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

	ROCEPHIN			
AP	+ ROCHE	EQ 250MG BASE/VIAL	N50585 001	DEC 21, 1984
AP	+	EQ 500MG BASE/VIAL	N50585 002	DEC 21, 1984

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

		ROCEPHIN			
AP	+	ROCHE	EQ 1GM BASE/VIAL	N50585 003	
				DEC 21, 1984	
	+		EQ 250MG BASE/VIAL	N50585 001	
				DEC 21, 1984	
	+		EQ 500MG BASE/VIAL	N50585 002	
				DEC 21, 1984	
	+		EQ 1GM BASE/VIAL	N50585 003	
				DEC 21, 1984	

CEFUROXIME SODIUM

INJECTABLE; INJECTION

		KEFUROX			
AP	+	LILLY	EQ 7.5GM BASE/VIAL	N62591 003	
				DEC 17, 1987	
AP			EQ 7.5GM BASE/VIAL	N62591 003	
				DEC 17, 1987	
		ZINACEF			
AP		GLAXO	EQ 7.5GM BASE/VIAL	N50558 004	
				OCT 23, 1986	
AP	+		EQ 7.5GM BASE/VIAL	N50558 004	
				OCT 23, 1986	

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

		CEPHALEXIN			
AB		APOTHECON	EQ 125MG BASE/5ML	N62986 001	
				APR 18, 1991	
AB			EQ 250MG BASE/5ML	N62987 001	
				JUL 25, 1989	
AB		SQUIBB MARK	EQ 125MG BASE/5ML	N62986 001	
				APR 18, 1991	
AB			EQ 250MG BASE/5ML	N62987 001	
				JUL 25, 1989	

CEPHRADINE

CAPSULE; ORAL

		VELOSEF			
AB	+	APOTHECON	250MG	N61764 001	> DLT >
AB	+		500MG	N61764 002	> ADD >

CEPHRADINE

CAPSULE; ORAL

		VELOSEF			
AB	+	ERSANA	250MG	N61764 001	> DLT >
AB	+		500MG	N61764 002	> ADD >

INJECTABLE; INJECTION

		VELOSEF			
	+	APOTHECON	250MG/VIAL	N61976 001	> DLT >
	+		500MG/VIAL	N61976 002	> DLT >
	+		1GM/VIAL	N61976 004	> DLT >
	+		2GM/VIAL	N61976 003	> ADD >
	+		4GM/VIAL	N61976 005	> DLT >
	+	SQUIBB	250MG/VIAL	N61976 001	> DLT >
	+		500MG/VIAL	N61976 002	> DLT >
	+		1GM/VIAL	N61976 004	> ADD >
	+		2GM/VIAL	N61976 003	> DLT >
	+		4GM/VIAL	N61976 005	> DLT >

POWDER FOR RECONSTITUTION; ORAL

		VELOSEF '125'			
AB	+	APOTHECON	125MG/5ML	N61763 001	> DLT >
AB	+	ERSANA	125MG/5ML	N61763 001	> DLT >
		VELOSEF '250'			
AB	+	APOTHECON	250MG/5ML	N61763 002	> DLT >
AB	+	ERSANA	250MG/5ML	N61763 002	> DLT >

CHLORAMPHENICOL

CAPSULE; ORAL

		MYCHEL			
AB		ARMENPHARM	250MG	N60851 001	> DLT >
AB		RACHELLE	250MG	N60851 001	> DLT >

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

		MENRIUM 10-4			
		ROCHE	10MG;0.4MG	N14740 006	> DLT >
	@		10MG;0.4MG	N14740 006	> ADD >
		MENRIUM 5-2			
		ROCHE	5MG;0.2MG	N14740 002	> DLT >
	@		5MG;0.2MG	N14740 002	> ADD >
		MENRIUM 5-4			
	+	ROCHE	5MG;0.4MG	N14740 004	> DLT >
	@		5MG;0.4MG	N14740 004	> ADD >

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE

AP	STERIS	10MG/ML	N83593 001
		100MG/ML	N86095 001
	@	10MG/ML	N83593 001
	@	100MG/ML	N86095 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

AP	STERIS	25MG/ML	N85591 001
	@	25MG/ML	N85591 001

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

AB	LEMMON	100MG	N88768 001 OCT 11, 1984
	@	100MG	N88768 001 OCT 11, 1984

GLUCAMIDE

AB	LEMMON	250MG	N88641 001 OCT 11, 1984
	@	250MG	N88641 001 OCT 11, 1984

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

AB	MUTUAL PHARM	25MG	N89738 001 SEP 19, 1988
AB		50MG	N89739 001 SEP 19, 1988
	@	25MG	N89738 001 SEP 19, 1988
	@	50MG	N89739 001 SEP 19, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
CHOLYBAR

+	PARKE DAVIS	EQ 4GM RESIN/BAR	N71621 001 MAY 26, 1988
		EQ 4GM RESIN/BAR	N71739 001 MAY 26, 1988
	@	EQ 4GM RESIN/BAR	N71621 001 MAY 26, 1988
	@	EQ 4GM RESIN/BAR	N71739 001 MAY 26, 1988

TABLET; ORAL
QUESTRAN

+	BRISTOL MYERS SQUIBB	EQ 1GM RESIN	N73403 001 APR 28, 1994
	@	EQ 1GM RESIN	N73403 001 APR 28, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	BAKER NORTON	200MG	N74424 001 JUL 28, 1995
AB		300MG	N74424 002 JUL 28, 1995
AB		400MG	N74424 003 JUL 28, 1995
AB		800MG	N74424 004 JUL 28, 1995
AB	GENEVA PHARMS	200MG	N74100 001 JAN 31, 1995
AB		300MG	N74100 002 JAN 31, 1995
AB		400MG	N74100 003 JAN 31, 1995
AB		800MG	N74100 004 JAN 31, 1995
AB	LEK LJUBLJANA	200MG	N74250 001 JUN 29, 1995
AB		300MG	N74250 002 JUN 29, 1995
AB		400MG	N74250 003 JUN 29, 1995
AB		800MG	N74250 004 JUN 29, 1995

CIMETIDINE

TABLET; ORAL

	CIMETIDINE				
AB	LEMMON	200MG	N74365 001 FEB 28, 1995	> ADD >	
AB		300MG	N74365 002 FEB 28, 1995	> DLT >	
AB		400MG	N74365 003 FEB 28, 1995	> DLT >	
AB		800MG	N74365 004 FEB 28, 1995		
AB	MOVA	300MG	N74340 001 JUN 23, 1995		
AB		400MG	N74340 002 JUN 23, 1995		
AB		800MG	N74339 001 JUN 23, 1995		
AB	ZENITH LABS	200MG	N74401 001 MAY 30, 1995		
AB		300MG	N74401 002 MAY 30, 1995	> DLT >	
AB		400MG	N74401 003 MAY 30, 1995	> ADD >	
AB		800MG	N74402 001 MAY 30, 1995	> ADD >	

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL				
AP	ABBOTT	EQ 300MG BASE/2ML	N74344 001 JAN 31, 1995	> DLT >	
AP		EQ 300MG BASE/2ML	N74345 001 JAN 31, 1995	> ADD >	
AP		EQ 300MG BASE/2ML	N74422 001 JAN 31, 1995	> ADD >	

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLEOCIN			
UPJOHN	EQ 1% BASE	N50537 002 FEB 22, 1994	

SWAB; TOPICAL

CLEOCIN			
UPJOHN	EQ 1% BASE	N50537 002 FEB 22, 1994	

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	TEMOVATE E				
BX	+ GLAXO	0.05%	N20340 001 JUN 17, 1994		
	TEMOVATE EMOLLIENT				
BX	+ GLAXO	0.05%	N20340 001 JUN 17, 1994		

OINTMENT; TOPICAL

	EMBELINE				
AB	DPT	0.05%	N74221 001 MAR 31, 1995		

CLOFIBRATE

CAPSULE; ORAL

	CLOFIBRATE				
AB	GENEVA PHARMS	500MG	N72191 001 MAY 02, 1988		
	@	500MG	N72191 001 MAY 02, 1988		

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	ANAFRANIL				
	BASEL PHARMS	50MG	N19906 002 DEC 29, 1989		
	+	75MG	N19906 003 DEC 29, 1989		
	+	50MG	N19906 002 DEC 29, 1989		
		75MG	N19906 003 DEC 29, 1989		

CLOTRIMAZOLE

SOLUTION; TOPICAL

	CLOTRIMAZOLE				
AT	LEMMON	1%	N73306 001 FEB 28, 1995		

CLOXACILLIN SODIUM

CAPSULE; ORAL

		CLOXACILLIN SODIUM		
AB	+	APOTHECON	**EQ 250MG BASE**	**N61452 001**
AB	+		**EQ 500MG BASE**	**N61452 002**
		TEGOPEN		
AB	+	APOTHECON	**EQ 250MG BASE**	**N61452 001**
AB	+		**EQ 500MG BASE**	**N61452 002**

CORTICOTROPIN

INJECTABLE; INJECTION

		ACTH		
AP		PARKE DAVIS	**40 UNITS/VIAL**	**N08317 004**
	@		40 UNITS/VIAL	N08317 004

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

		CROLOM		
AT		BAUSCH AND LOMB	**4%**	**N74443 001** JAN 30, 1995
		OPTICROM		
AT	+	FISONS	**4%**	**N18155 001** OCT 03, 1984

CUPRIC SULFATE

INJECTABLE; INJECTION

> DLT >		**CUPRIC SULFATE**		
> DLT >	+	**FUJISAWA**	**EQ 0.4MG COPPER/ML**	**N19350 001** MAY 05, 1987
> DLT >	@		EQ 0.4MG COPPER/ML	N19350 001 MAY 05, 1987
> ADD >				
> ADD >				

CYANOCOBALAMIN

INJECTABLE; INJECTION

		CYANOCOBALAMIN		
AP		AKORN	**1MG/ML**	**N87969 001** NOV 10, 1983
	@		1MG/ML	N87969 001 NOV 10, 1983
	@	WARNER CHILCOTT	1MG/ML	N07085 002

CYANOCOBALAMIN

INJECTABLE; INJECTION

		RUBRAMIN PC		
AP	+	SQUIBB	**0.1MG/ML**	**N06799 002**
	@		0.1MG/ML	N06799 002
		SYTOBEX		
AP		PARKE DAVIS	**1MG/ML**	**N07085 002**

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

		CYCLOBENZAPRINE HCL		
AB		BARR	**10MG**	**N73541 001** MAY 23, 1995

CYCLOSPORINE

CAPSULE; ORAL

		NEORAL		
		SANDOZ	25MG	N50715 001 JUL 14, 1995
			50MG	N50715 003 JUL 14, 1995
	+		100MG	N50715 002 JUL 14, 1995

SOLUTION; ORAL

		NEORAL		
	+	SANDOZ	100MG/ML	N50716 001 JUL 14, 1995
		SANDIMMUNE		
		SANDOZ	100MG/ML	N50574 001 NOV 14, 1983
	+		100MG/ML	N50574 001 NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

		CYPROHEPTADINE HCL		
AA		ASCOT	**4MG**	**N87685 001** OCT 25, 1982
	@		4MG	N87685 001 OCT 25, 1982

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL

AP	CETUS BEN VENUE	EQ 20MG BASE/VIAL	N64103 001 FEB 03, 1995	

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DDAVP

+	RHONE POULENC	0.015MG/ML	N18938 002 APR 25, 1995	

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE

+	RHONE POULENC RORER	0.15MG/INH	N20355 001 MAR 07, 1994	> ADD >

STIMATE

+	RHONE POULENC RORER	0.15MG/INH	N20355 001 MAR 07, 1994	> ADD >

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGEN

AB	+ ORGANON	0.15MG;0.03MG	N20071 001 DEC 10, 1992	
	@	0.15MG;0.03MG	N20071 001 DEC 10, 1992	

ORTHO-CEPT

AB	JOHNSON RW	0.15MG;0.03MG	N20301 001 DEC 14, 1992	
		0.15MG;0.03MG	N20301 001 DEC 14, 1992	

DEXAMETHASONE

AEROSOL; TOPICAL
DECASPRAY

+	MERCK SHARP DOHME	0.4%	N12731 002
+		0.04%	N12731 002

TABLET; ORAL
HEXADROL

BP	ORGANON	0.5MG	N12675 004

DEXAMETHASONE

TABLET; ORAL
HEXADROL

BP	ORGANON	0.75MG	N12675 007
BP		1.5MG	N12675 009
@		0.5MG	N12675 004
@		0.75MG	N12675 007
@		1.5MG	N12675 009

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE

> DLT >				
> DLT >				
AP	FUJISAWA	EQ 4MG PHOSPHATE/ML	N88448 001 JAN 25, 1984	
> ADD >	@	EQ 4MG PHOSPHATE/ML	N88448 001 JAN 25, 1984	

DEXAMETHASONE SODIUM PHOSPHATE

AP	AKORN	EQ 4MG PHOSPHATE/ML	N84493 001	
@		EQ 4MG PHOSPHATE/ML	N84493 001	

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
ZINECARD

+	PHARMACIA	EQ 250MG BASE/VIAL	N20212 001 MAY 26, 1995
+		EQ 500MG BASE/VIAL	N20212 002 MAY 26, 1995

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 2.5% IN PLASTIC CONTAINER

	MCGAW	2.5GM/100ML	N19626 001 FEB 02, 1988
@		2.5GM/100ML	N19626 001 FEB 02, 1988

DEXTROSE 7.7% IN PLASTIC CONTAINER

	MCGAW	7.7GM/100ML	N19626 003 FEB 02, 1988
@		7.7GM/100ML	N19626 003 FEB 02, 1988

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

AP	FUJISAWA	5MG/ML	N70662 001 JUN 25, 1986	
@		5MG/ML	N70662 001 JUN 25, 1986	

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM

	GEIGY	25MG	N20142 001 NOV 24, 1993	
@		25MG	N20142 001 NOV 24, 1993	

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

AB	ROXANE	25MG	N74391 001 JUN 29, 1995	
AB		50MG	N74391 002 JUN 29, 1995	
AB		75MG	N74391 003 JUN 29, 1995	
	VOLTAREN			
AB +	GEIGY	25MG	N19201 001 JUL 28, 1988	
AB +		50MG	N19201 002 JUL 28, 1988	
AB +		75MG	N19201 003 JUL 28, 1988	

DICLOXACILLIN SODIUM

CAPSULE; ORAL
DICLOXACILLIN SODIUM

AB	APOTHECON	EQ 250MG BASE	N61454 001	
AB		EQ 500MG BASE	N61454 003	
		EQ 125MG BASE	N61454 002	
	DYNAPEN			
AB	APOTHECON	EQ 250MG BASE	N61454 001	
AB		EQ 500MG BASE	N61454 003	

DICLOXACILLIN SODIUM

CAPSULE; ORAL
DYNAPEN

	APOTHECON	EQ 125MG BASE	N61454 002	

POWDER FOR RECONSTITUTION; ORAL
DICLOXACILLIN SODIUM

AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001	
	DYNAPEN			
AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001	

DIDANOSINE

POWDER FOR RECONSTITUTION; ORAL
VIDEX

	BRISTOL MYERS SQUIBB	250MG/PACKET	N20155 005 OCT 09, 1991	
+		375MG/PACKET	N20155 006 OCT 09, 1991	
+		250MG/PACKET	N20155 005 OCT 09, 1991	
@		375MG/PACKET	N20155 006 OCT 09, 1991	

DIFLORASONE DIACETATE

CREAM; TOPICAL
PSORCON

BX	DERMIK	0.05%	N20205 001 NOV 20, 1992	
BX +		0.05%	N20205 001 NOV 20, 1992	

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
CARDIZEM

> ADD >	+ HOECHST MARION RSSL	25MG/VIAL	N20027 003 AUG 18, 1995	> ADD >

TABLET; ORAL
DILTIAZEM HCL

AB	LEMMON	30MG	N74185 001 MAY 31, 1995	

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

AB	LEMMON	60MG	N74185 002 MAY 31, 1995
AB		90MG	N74185 003 MAY 31, 1995
AB		120MG	N74185 004 MAY 31, 1995
AB	ZENITH LABS	30MG	N74168 001 MAR 03, 1995
AB		60MG	N74168 002 MAR 03, 1995
AB		90MG	N74168 003 MAR 03, 1995
AB		120MG	N74168 004 MAR 03, 1995

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

AP	STERIS	50MG/ML	N83531 001
	@	50MG/ML	N83531 001

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	CONTROLLED THERAP	10MG	N20411 001 MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	WEST WARD PHARM	50MG	N83567 001
	@	50MG	N83567 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DIPIVEFRIN HCL

AT	BAUSCH AND LOMB	0.1%	N74188 001 MAY 19, 1995

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC

+	LILLY	250MG	N50678 001 JUN 19, 1995

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DEPAKOTE

+	ABBOTT	EQ 125MG BASE	N19680 001 SEP 12, 1989
+		EQ 125MG VALPROIC ACID	N19680 001 SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE

	ABBOTT	EQ 125MG BASE	N18723 003 OCT 26, 1984
		EQ 250MG BASE	N18723 001 MAR 10, 1983
+		EQ 500MG BASE	N18723 002 MAR 10, 1983
		EQ 125MG VALPROIC ACID	N18723 003 OCT 26, 1984
		EQ 250MG VALPROIC ACID	N18723 001 MAR 10, 1983
+		EQ 500MG VALPROIC ACID	N18723 002 MAR 10, 1983

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP	ASTRA	EQ 12.5MG BASE/ML	N74098 001 FEB 21, 1995
AP	SANOFI WINTHROP	EQ 12.5MG BASE/ML	N74292 001 FEB 16, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL IN DEXTROSE 5%

> ADD >				
> ADD >				
> ADD >	AP	+	ABBOTT	1.6MG/ML	N20542 001 AUG 30, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		INTROPIN				
AP	+	DUPONT MERCK	**40MG/ML**	**N17395 001**		
AP	+		**80MG/ML**	**N17395 002**		
AP	+		**160MG/ML**	**N17395 003**		
AP	+	FAULDING	**40MG/ML**	**N17395 001**		
AP	+		**80MG/ML**	**N17395 002**	> ADD >	
AP	+		**160MG/ML**	**N17395 003**	> ADD >	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	DOXORUBICIN HCL			
AP	GENSIA	**2MG/ML**	**N64140 001**	JUL 28, 1995
AP		**200MG/100ML**	**N64140 002**	JUL 28, 1995
AP	PHARMACHEMIE (NL)	**2MG/ML**	**N63336 001**	FEB 28, 1995
AP		**200MG/100ML**	**N63336 004**	FEB 28, 1995

DOXYCYCLINE

CAPSULE; ORAL

	DOXYCYCLINE MONOHYDRATE			
+	VINTAGE PHARMS	EQ 100MG BASE	N50641 001	DEC 29, 1989
	MONODOX			
+	OCLASSEN	EQ 100MG BASE	N50641 001	DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

	DOXYCYCLINE HYCLATE			
AB	PVT FORM	**EQ 50MG BASE**	**N62631 001**	JUL 24, 1986
AB		**EQ 100MG BASE**	**N62631 002**	JUL 24, 1986
@		EQ 50MG BASE	N62631 001	JUL 24, 1986
@		EQ 100MG BASE	N62631 002	JUL 24, 1986

DROPERIDOL

INJECTABLE; INJECTION

	DROPERIDOL			
AP	DUPONT MERCK	**2.5MG/ML**	**N71645 001**	APR 07, 1988
AP	FAULDING	**2.5MG/ML**	**N71645 001**	APR 07, 1988
AP	SANOFI WINTHROP	**2.5MG/ML**	**N72272 001**	AUG 31, 1995

EDETATE DISODIUM

INJECTABLE; INJECTION

	SODIUM VERSENATE		
+	3M	200MG/ML	N10573 001
@		200MG/ML	N10573 001

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC		
MERCK	5MG;12.5MG	N19221 003 JUL 12, 1995

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC			
AB	FAULDING	**250MG**	**N50536 001**	
AB	+	**250MG**	**N50536 001**	
AB	+ PARKE DAVIS	**250MG**	**N62338 001**	
AB	+	**250MG**	**N62618 001**	SEP 25, 1985
@		250MG	N62338 001	
@		250MG	N62618 001	SEP 25, 1985

TABLET, DELAYED RELEASE; ORAL

	ROBINMYCIN			
AB	ROBINS AH	**250MG**	**N61633 001**	
@		250MG	N61633 001	

ERYTHROMYCIN ESTOLATE

DROPS; ORAL
ILOSONE
+ DISTA — EQ 100MG BASE/ML — N61894 003

SUSPENSION/DROPS; ORAL
ILOSONE
+ DISTA — EQ 100MG BASE/ML — N61894 003

ERYTHROMYCIN ETHYLSUCCINATE

DROPS; ORAL
PEDIAMYCIN
+ ROSS LABS — EQ 100MG BASE/2.5ML — N62305 002

SUSPENSION; ORAL
WYAMYCIN E
AB WYETH AYERST — EQ 200MG BASE/5ML — N62123 002
AB — EQ 400MG BASE/5ML — N62123 001
@ — EQ 200MG BASE/5ML — N62123 002
@ — EQ 400MG BASE/5ML — N62123 001

SUSPENSION/DROPS; ORAL
PEDIAMYCIN
+ ROSS LABS — EQ 100MG BASE/2.5ML — N62305 002

ERYTHROMYCIN STEARATE

TABLET; ORAL
ETHRIL 250
AB SQUIBB — EQ 250MG BASE — N61605 001
@ — EQ 250MG BASE — N61605 001
ETHRIL 500
AB SQUIBB — EQ 500MG BASE — N61605 002
@ — EQ 500MG BASE — N61605 002

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
BX 3M — 0.05MG/24HR — N20375 001 DEC 22, 1994
BX + — 0.05MG/24HR — N20375 001 DEC 22, 1994

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
BX 3M — 0.1MG/24HR — N20375 002 DEC 22, 1994
BX + — 0.1MG/24HR — N20375 002 DEC 22, 1994
VIVELLE
BX — 0.05MG/24HR — N20323 002 OCT 28, 1994
BX — 0.1MG/24HR — N20323 004 OCT 28, 1994
— 0.0375MG/24HR — N20323 001 OCT 28, 1994
— 0.075MG/24HR — N20323 003 OCT 28, 1994
BX + CIBA GEIGY — 0.05MG/24HR — N20323 002 OCT 28, 1994
BX + — 0.1MG/24HR — N20323 004 OCT 28, 1994
+ — 0.0375MG/24HR — N20323 001 OCT 28, 1994
+ — 0.075MG/24HR — N20323 003 OCT 28, 1994

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN
AQ + SQUIBB — 10MG/ML — N09402 002
+ — 10MG/ML — N09402 002
ESTRADIOL VALERATE
AQ STERIS — 10MG/ML — N83546 001
@ — 10MG/ML — N83546 001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
OVCON-35
+ BRISTOL MYERS SQUIBB — 0.035MG;0.4MG — N18127 001
+ MEAD JOHNSON — 0.035MG;0.4MG — N18127 001
OVCON-50
@ BRISTOL MYERS SQUIBB — 0.05MG;1MG — N18128 001
+ MEAD JOHNSON — 0.05MG;1MG — N18128 001

TABLET; ORAL-28
OVCON-35
BRISTOL MYERS SQUIBB — 0.035MG;0.4MG — N17716 001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

OVCON-35			
MEAD JOHNSON	0.035MG;0.4MG	N17716 001	
OVCON-50			
BRISTOL MYERS SQUIBB	0.05MG;1MG	N17576 001	
MEAD JOHNSON	0.05MG;1MG	N17576 001	

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL

PARSIDOL			
PARKE DAVIS	10MG	N09078 003	
	50MG	N09078 006	
+	100MG	N09078 008	
@	10MG	N09078 003	
@	50MG	N09078 006	
@	100MG	N09078 008	

ETOPOSIDE

INJECTABLE; INJECTION

		ETOPOSIDE			
> ADD >	AP	ABBOTT	20MG/ML	N74320 001	
> ADD >				AUG 30, 1995	
> ADD >	AP		20MG/ML	N74351 001	
> ADD >				AUG 30, 1995	
	AP	BEN VENUE	20MG/ML	N74290 001	
				JUL 17, 1995	
	AP	GENSIA	20MG/ML	N74510 001	
				JUN 29, 1995	
		TOPOSAR			
	AP	PHARMACIA	20MG/ML	N74166 001	
				FEB 27, 1995	

FENOFIBRATE

CAPSULE; ORAL

LIPIDIL					
+	LABS FOURNIER	100MG	N19304 001	> DLT >	
			DEC 31, 1993	> DLT >	
@		100MG	N19304 001	> ADD >	
			DEC 31, 1993	> ADD >	

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF			
+	APOTHECON	0.1MG	N10060 001
+	SQUIBB	0.1MG	N10060 001

FLUNISOLIDE

SPRAY, METERED; NASAL

	NASALIDE			
BX	+ SYNTEX	0.025MG/INH	N18148 001	
	NASAREL			
BX	+ SYNTEX	0.025MG/INH	N20409 001	
			MAR 08, 1995	

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

		FLUOCINOLONE ACETONIDE		
AT	+	HAMILTON PHARMA CA	0.01%	N12787 004
AT	+		0.025%	N12787 002
AT	+		0.025%	N12787 005
	+		0.2%	N16161 002
		SYNALAR		
AT	+	SYNTEX	0.01%	N12787 004
AT	+		0.025%	N12787 002
		SYNALAR-HP		
	+	SYNTEX	0.2%	N16161 002
		SYNEMOL		
AT	+	SYNTEX	0.025%	N12787 005

OINTMENT; TOPICAL

		FLUOCINOLONE ACETONIDE		
AT	+	HAMILTON PHARMA CA	0.025%	N13960 001
		SYNALAR		
AT	+	SYNTEX	0.025%	N13960 001

SOLUTION; TOPICAL

		FLUOCINOLONE ACETONIDE		
AT	+	HAMILTON PHARMA CA	0.01%	N15296 001
AT		PHARMADERM	0.01%	N88048 001
				DEC 16, 1982
	@		0.01%	N88048 001
				DEC 16, 1982
		SYNALAR		
AT	+	SYNTEX	0.01%	N15296 001

FLUOCINONIDE

CREAM; TOPICAL

		FLUOCINONIDE		
AB	+	HAMILTON PHARMA CA	0.05%	N16908 002
		FLUOCINONIDE EMOLLIENT BASE		
AB		HAMILTON PHARMA CA	0.05%	N16908 003
		FLUOCINONIDE EMULSIFIED BASE		
AB		NMC	0.05%	N74204 001 JUN 13, 1995
		LIDEX		
AB	+	SYNTEX	0.05%	N16908 002
		LIDEX-E		
AB		SYNTEX	0.05%	N16908 003

GEL; TOPICAL

		FLUOCINONIDE		
AB	+	HAMILTON PHARMA CA	0.05%	N17373 001
		LIDEX		
AB	+	SYNTEX	0.05%	N17373 001

OINTMENT; TOPICAL

		FLUOCINONIDE		
AB	+	HAMILTON PHARMA CA	0.05%	N16909 002
		LIDEX		
AB	+	SYNTEX	0.05%	N16909 002

SOLUTION; TOPICAL

		FLUOCINONIDE		
AT		FOUGERA	0.05%	N72934 001 FEB 27, 1995
AT	+	HAMILTON PHARMA CA	0.05%	N18849 001 APR 06, 1984
		LIDEX		
AT	+	SYNTEX	0.05%	N18849 001 APR 06, 1984

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		PERMITIL		
AA		SCHERING	5MG/ML	N16008 001
AA	+		5MG/ML	N16008 001

FLURBIPROFEN

TABLET; ORAL

		FLURBIPROFEN		
AB		GENEVA PHARMS	50MG	N74448 001 JUL 28, 1995
AB			100MG	N74448 002 JUL 28, 1995
AB		LEMMON	100MG	N74431 001 MAY 31, 1995
AB		NOVOPHARM	50MG	N74405 002 MAY 24, 1995
AB			100MG	N74405 001 MAY 24, 1995
AB		ZENITH LABS	50MG	N74411 001 MAY 31, 1995
AB			100MG	N74411 002 MAY 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

		FLURBIPROFEN SODIUM		
AT		BAUSCH AND LOMB	0.03%	N74447 001 JAN 04, 1995
		OCUFEN		
AT	+	ALLERGAN	0.03%	N19404 001 DEC 31, 1986

FOSINOPRIL SODIUM

TABLET; ORAL

		MONOPRIL		
	+	BRISTOL MYERS SQUIBB	20MG	N19915 003 MAY 16, 1991
			20MG	N19915 003 MAY 16, 1991
	+		40MG	N19915 004 MAR 28, 1995

GEMFIBROZIL

CAPSULE; ORAL

		GEMFIBROZIL		
AB	+	MYLAN	300MG	N73466 001 JAN 25, 1993

GEMFIBROZIL

CAPSULE; ORAL

	GEMFIBROZIL			
	@ MYLAN	300MG	N73466 001	
			JAN 25, 1993	
AB	PUREPAC PHARM	**300MG**	**N72929 001**	
			JAN 29, 1993	
	@	300MG	N72929 001	
			JAN 29, 1993	
	LOPID			
AB	+ PARKE DAVIS	**300MG**	**N18422 002**	
	@	300MG	N18422 002	

TABLET; ORAL

	GEMFIBROZIL		
AB	CHELSEA LABS	**600MG**	**N74442 001**
			APR 28, 1995
AB	MYLAN	**600MG**	**N74452 001**
			FEB 16, 1995

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

>ADD>	**GENTAMICIN SULFATE**			
>ADD> **AT**	ADV REMEDIES	**EQ 0.3% BASE**	**N64093 001**	
>ADD>			AUG 31, 1995	

OINTMENT; TOPICAL

	GENTAMICIN SULFATE			
>DLT> **AT**	PHARMADERM	**EQ 0.1% BASE**	**N62534 001**	
>DLT>			OCT 10, 1984	
>ADD>	@	EQ 0.1% BASE	N62534 001	
>ADD>			OCT 10, 1984	

SOLUTION/DROPS; OPHTHALMIC

	GENTAMICIN SULFATE		
AT	ALCON	**EQ 0.3% BASE**	**N62196 001**

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE		
AB	ALPHAPHARM	**5MG**	**N74438 001**
			JUN 20, 1995
AB		**10MG**	**N74438 002**
			JUN 20, 1995

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE		
AB	BAKER NORTON	**5MG**	**N74497 001**
			AUG 31, 1995
AB		**10MG**	**N74497 002**
			AUG 31, 1995
AB	GENEVA PHARMS	**5MG**	**N74305 001**
			APR 07, 1995
AB		**10MG**	**N74305 002**
			APR 07, 1995
AB	INVAMED	**5MG**	**N74542 001**
			JUN 20, 1995
AB		**10MG**	**N74542 002**
			JUN 20, 1995
AB	WATSON LABS	**5MG**	**N74223 001**
			FEB 27, 1995
AB		**10MG**	**N74223 002**
			FEB 27, 1995

GLYBURIDE

TABLET; ORAL

	GLUBATE		
	@ HOECHST ROUSSEL	1.5MG	N20055 001
			APR 17, 1992
	@	3MG	N20055 002
			APR 17, 1992
	GLYBURIDE		
AB	NOVOPHARM	**1.25MG**	**N74388 001**
			AUG 29, 1995
AB		**2.5MG**	**N74388 002**
			AUG 29, 1995
AB		**5MG**	**N74388 003**
			AUG 29, 1995
	GLYBURIDE (MICRONIZED)		
AB	HOECHST ROUSSEL	**1.5MG**	**N20055 001**
			APR 17, 1992
AB		**3MG**	**N20055 002**
			APR 17, 1992
	GLYNASE		
AB	UPJOHN	**1.5MG**	**N20051 001**
			MAR 04, 1992
AB		**3MG**	**N20051 002**
			MAR 04, 1992
	MICRONASE		
>ADD> **AB**	UPJOHN	**1.25MG**	**N17498 001**
>ADD>			MAY 01, 1984

GLYBURIDE

TABLET; ORAL

		MICRONASE			
> ADD >	**AB**	UPJOHN	**2.5MG**		**N17498 002**
> ADD					MAY 01, 1984
> ADD >	**AB**	+	**5MG**		**N17498 003**
> ADD >					MAY 01, 1984

GLYCINE

SOLUTION; IRRIGATION

	GLYCINE 1.5% IN PLASTIC CONTAINER			
AT	BAXTER	**1.5GM/100ML**		**N18522 001**
				FEB 19, 1982
	@	1.5GM/100ML		N18522 001
				FEB 19, 1982

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

	KYTRIL			
	+ SMITHKLINE BEECHAM	EQ 1MG BASE		N20305 001
				MAR 16, 1995

GUANABENZ ACETATE

TABLET; ORAL

	GUANABENZ ACETATE			
AB	ZENITH LABS	**EQ 4MG BASE**		**N74149 001**
				APR 07, 1995
		EQ 8MG BASE		N74149 002
				APR 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	TENEX			
	ROBINS AH	1MG		N19032 001
				OCT 27, 1986
	+	2MG		N19032 002
				NOV 07, 1988
	@	3MG		N19032 003
				NOV 07, 1988

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	TENEX			
	ROBINS AH	EQ 1MG BASE		N19032 001
				OCT 27, 1986
	+	EQ 2MG BASE		N19032 002
				NOV 07, 1988
	@	EQ 3MG BASE		N19032 003
				NOV 07, 1988

HALCINONIDE

CREAM; TOPICAL

	HALOG			
AT	+ WESTWOOD SQUIBB	**0.1%**		**N17556 001**
	+	0.1%		N17556 001
	HALOG-E			
AT	WESTWOOD SQUIBB	**0.1%**		**N18234 001**
		0.1%		N18234 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

	CALCIPARINE			
	+ CHOAY	25,000 UNITS/ML		N18237 001
	@ SANOFI WINTHROP	25,000 UNITS/ML		N18237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN LOCK FLUSH			
AP	SANOFI WINTHROP	**10 UNITS/ML**		**N40082 001**
				FEB 28, 1995
AP		**100 UNITS/ML**		**N40082 002**
				FEB 28, 1995
	HEPARIN SODIUM			
AP	+ ABBOTT	**2,500 UNITS/ML**		**N05264 014**
				APR 07, 1986
	+	2,000 UNITS/ML		N05264 013
				APR 07, 1986
AP	ELKINS SINN	**10,000 UNITS/ML**		**N17037 013**
				APR 07, 1986
AP		**5,000 UNITS/0.5ML**		**N17037 013**
				APR 07, 1986
AP	PHARMA SERVE NY	**1,000 UNITS/ML**		**N86129 001**

HEPARIN SODIUM

INJECTABLE: INJECTION

	HEPARIN SODIUM			
AP	WYETH AYERST	2,500 UNITS/ML	N17007 007	
AP	+	2,500 UNITS/ML	N17007 007	
	HEPARIN SODIUM 1000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	N19130 001	DEC 31, 1984
	@	200 UNITS/100ML	N19130 001	DEC 31, 1984
	HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	N19042 001	MAR 29, 1985
	@	200 UNITS/100ML	N19042 001	MAR 29, 1985
	HEPARIN SODIUM 2000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	N19130 003	DEC 31, 1984
	@	200 UNITS/100ML	N19130 003	DEC 31, 1984
	HEPARIN SODIUM 2000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	N19042 002	MAR 29, 1985
	@	200 UNITS/100ML	N19042 002	MAR 29, 1985
	HEPARIN SODIUM 5000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	1,000 UNITS/100ML	N19130 002	DEC 31, 1984
	@	1,000 UNITS/100ML	N19130 002	DEC 31, 1984
	HEPARIN SODIUM PRESERVATIVE FREE			
AP	+ ABBOTT	2,500 UNITS/ML	N05264 014	APR 07, 1986
	+	2,000 UNITS/ML	N05264 013	APR 07, 1986
AP	FUJISAWA	1,000 UNITS/ML	N17029 010	APR 28, 1986
AP	+	1,000 UNITS/ML	N17029 010	APR 28, 1986
AP	PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	
AP	STERLING WINTHROP	10,000 UNITS/ML	N89522 001	MAY 04, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN SODIUM PRESERVATIVE FREE			
AP	+ STERLING WINTHROP	10,000 UNITS/ML	N89522 001	MAY 04, 1987
	LIQUAEMIN LOCK FLUSH			
AP	ORGANON	100 UNITS/ML	N00552 007	
	@	100 UNITS/ML	N00552 007	
	LIQUAEMIN SODIUM			
AP	ORGANON	1,000 UNITS/ML	N00552 004	
AP		5,000 UNITS/ML	N00552 003	
AP		10,000 UNITS/ML	N00552 005	
	@	1,000 UNITS/ML	N00552 004	
	@	5,000 UNITS/ML	N00552 003	
	@	10,000 UNITS/ML	N00552 005	

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	DRALZINE			
AA	LEMMON	25MG	N84301 001	
	@	25MG	N84301 001	
	HYDRALAZINE HCL			
AA	HALSEY	50MG	N89222 001	JAN 22, 1986
	@	50MG	N89222 001	JAN 22, 1986

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	APRESOLINE-ESIDRIX			
	+ CIBA	25MG;15MG	N12026 002	
	@	25MG;15MG	N12026 002	

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE			
AB	ASCOT	50MG	N87540 001	FEB 03, 1982
	@	50MG	N87540 001	FEB 03, 1982
AB	INWOOD LABS	25MG	N85067 001	
	@	25MG	N85067 001	

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
HYZAAR
+ MERCK 12.5MG;50MG N20387 001 APR 28, 1995

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL
LOPRESSOR HCT
CIBA 25MG;50MG N18303 001 DEC 31, 1984
25MG;100MG N18303 002 DEC 31, 1984
+ 50MG;100MG N18303 003 DEC 31, 1984

LOPRESSOR HCT 100/25
CIBA 25MG;100MG N18303 002 DEC 31, 1984

LOPRESSOR HCT 100/50
+ CIBA 50MG;100MG N18303 003 DEC 31, 1984

LOPRESSOR HCT 50/25
CIBA 25MG;50MG N18303 001 DEC 31, 1984

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE
AB WARNER CHILCOTT 25MG;80MG N71772 001 JAN 26, 1988
@ 25MG;80MG N71772 001 JAN 26, 1988

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB ZENITH LABS 25MG;50MG N74259 001 MAR 30, 1995

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE
AT CLAY PARK 0.5% N84970 002
AT 1% N85026 001
@ 0.5% N84970 002
@ 1% N85026 001

ENEMA; RECTAL
CORTENEMA
+ 100MG/60ML N16199 001
BR + SOLVAY 100MG/60ML N16199 001
HYDROCORTISONE
BR COPLEY PHARM 100MG/60ML N74171 001 MAY 27, 1994
@ 100MG/60ML N74171 001 MAY 27, 1994

LOTION; TOPICAL
HYDROCORTISONE
AT CLAY PARK 0.5% N85662 001
@ 0.5% N85662 001

OINTMENT; TOPICAL
HYDROCORTISONE
CLAY PARK 0.5% N84969 003
@ 0.5% N84969 003

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
CORTISPORIN
AT + BURROUGHS WELLCOME 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50479 001
AT + 10.1MG/ML;EQ 3.5MG BASE/ML; 12,000 UNITS/ML N50479 001

HYDROCORTISONE; UREA

CREAM; TOPICAL
ALPHADERM
AT VIVAN 1%;10% N86008 001
@ 1%;10% N86008 001
CALMURID HC
AT + PHARMACIA 1%;10% N83947 001
@ 1%;10% N83947 001

HYDROCORTISONE ACETATE

AEROSOL; RECTAL
CORTIFOAM
+ REED AND CARNRICK 10% N17351 001 FEB 10, 1982
+ SPKU 10% N17351 001 FEB 10, 1982

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL; TOPICAL
PROCTOFOAM HC
> DLT > BX REED AND CARNRICK 1%;1% N86195 001
> ADD > BX SPKU 1%;1% N86195 001

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
DILAUDID-HP
> ADD > **AP** + KNOLL PHARM **10MG/ML** **N19034 001** JAN 11, 1984
> ADD >
> ADD > **HYDROMORPHONE HCL**
> ADD > **AP** STERIS **10MG/ML** **N74317 001** AUG 23, 1995
> ADD >

HYDROXYUREA

CAPSULE; ORAL
HYDREA
> ADD > **AB** + SQUIBB **500MG** **N16295 001**
> ADD > **HYDROXYUREA**
> ADD > **AB** ROXANE **500MG** **N74476 001** AUG 18, 1995
> ADD >

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL
AP PHARMAFAIR **50MG/ML** **N88881 001** FEB 14, 1986
@ 50MG/ML N88881 001 FEB 14, 1986
AP STERIS **25MG/ML** **N87274 001**
AP **50MG/ML** **N87274 002**

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL
@ STERIS 25MG/ML N87274 001
@ 50MG/ML N87274 002

SYRUP; ORAL
HYDROXYZINE HCL
AA BARRE **10MG/5ML** **N88785 001** FEB 03, 1988
@ 10MG/5ML N88785 001 FEB 03, 1988

TABLET; ORAL
HYDROXYZINE HCL
> DLT > **AB** HALSEY **50MG** **N89396 001** MAY 02, 1988
> DLT >
> ADD > @ 50MG N89396 001 MAY 02, 1988
> ADD >

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S MOTRIN
BX + MCNEIL CONS PRODS 100MG/5ML N19842 001 SEP 19, 1989

PEDIA PROFEN
BX + MCNEIL CONS PRODS 100MG/5ML N19842 001 SEP 19, 1989

SUSPENSION/DROPS; ORAL
MOTRIN
+ MCNEIL CONS PRODS 40MG/ML N20476 001 MAY 25, 1995

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE
AB ZENITH LABS **2.5MG** **N74299 001** JUL 27, 1995

LOZOL
AB + RHONE POULENC RORER **2.5MG** **N18538 001** JUL 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

> DLT >	DECABID			
> DLT >	LILLY	EQ 50MG BASE	N19693 001	DEC 29, 1989
> DLT >		EQ 75MG BASE	N19693 002	DEC 29, 1989
> DLT >	+	EQ 100MG BASE	N19693 003	DEC 29, 1989
> ADD >	@	EQ 50MG BASE	N19693 001	DEC 29, 1989
> ADD >	@	EQ 75MG BASE	N19693 002	DEC 29, 1989
> ADD >	@	EQ 100MG BASE	N19693 003	DEC 29, 1989

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE			
+	CYPROS	100MG/ML	N02282 001
+	ISO TEX	100MG/ML	N02282 001

IOCETAMIC ACID

TABLET; ORAL

CHOLEBRINE			
+	MALLINCKRODT	750MG	N17129 001
@		750MG	N17129 001

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST				
+	BERLEX	EQ 150MG IODINE/ML	N20220 004	MAY 10, 1995
+		EQ 240MG IODINE/ML	N20220 003	MAY 10, 1995
+		EQ 300MG IODINE/ML	N20220 002	MAY 10, 1995
+		EQ 370MG IODINE/ML	N20220 001	MAY 10, 1995

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY			
+	MALLINCKRODT	80%	N13319 001
@		80%	N13319 001

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST			
@	BERLEX	EQ 190MG IODINE/ML	N19580 001 DEC 07, 1989
@		EQ 240MG IODINE/ML	N19580 002 DEC 07, 1989
		EQ 190MG IODINE/ML	N19580 001 DEC 07, 1989
		EQ 240MG IODINE/ML	N19580 002 DEC 07, 1989

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HCL S/F				
AN	+	DEY	1%	N89252 001 SEP 15, 1986
	@		1%	N89252 001 SEP 15, 1986

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE				
AN		MARSAM	99.9%	N74393 001 MAY 12, 1995
AN		RHONE POULENC	99.9%	N74502 001 JUN 27, 1995

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR				
BC		REED AND CARNRICK	40MG	N19790 001 SEP 02, 1988

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

BC	SPKU	40MG	N19790 001	SEP 02, 1988

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR

	@ SCHERING	30MG	N20225 001	AUG 12, 1993
	+	60MG	N20225 002	AUG 12, 1993
	+	120MG	N20225 003	MAR 30, 1995
	@ SCHERING PLOUGH	30MG	N20225 001	AUG 12, 1993
	+	60MG	N20225 002	AUG 12, 1993

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN

AP	**ELKINS SINN**	**EQ 75MG BASE/2ML**	**N62324 001**	
AP		**EQ 500MG BASE/2ML**	**N62324 002**	
AP		**EQ 1GM BASE/3ML**	**N62324 003**	
	@	EQ 75MG BASE/2ML	N62324 001	
	@	EQ 500MG BASE/2ML	N62324 002	
	@	EQ 1GM BASE/3ML	N62324 003	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

	+ WYETH AYERST	100MG	N19816 003	FEB 08, 1995
	+	150MG	N19816 002	FEB 08, 1995

LACTULOSE

SOLUTION; ORAL
LACTULOSE

AA	HI TECH PHARMA	**10GM/15ML**	**N74076 001**	JUL 03, 1995

SOLUTION; ORAL, RECTAL
LACTULOSE

AA	HI TECH PHARMA	**10GM/15ML**	**N74077 001**	JUL 03, 1995

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID

	TAP HOLDINGS	15MG	N20406 001	MAY 10, 1995
	+	30MG	N20406 002	MAY 10, 1995

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

	+ CETUS BEN VENUE	EQ 200MG BASE/VIAL	N40056 001	MAY 23, 1995

WELLCOVORIN

AP	**BURROUGHS WELLCOME**	**EQ 50MG BASE/VIAL**	**N89465 001**	JAN 23, 1989
	+	EQ 25MG BASE/VIAL	N89833 001	JAN 23, 1989
	@	EQ 25MG BASE/VIAL	N89833 001	JAN 23, 1989
	@	EQ 50MG BASE/VIAL	N89465 001	JAN 23, 1989

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON

	TAP HOLDINGS	5MG/ML	N20263 001	APR 16, 1993
	+	1MG/0.2ML	N19010 001	APR 09, 1985

>DLT>
>DLT>

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON
\+ TAP PHARMS 5MG/ML N19010 001 APR 09, 1985

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
AP AKORN 1% N85037 001
AP 2% N85037 002
@ 1% N85037 001
@ 2% N85037 002
AP SANOFI WINTHROP 1% N40013 001 JUN 23, 1995
AP 2% N40078 001 JUN 23, 1995

SOLUTION; ORAL
LIDOCAINE HCL
AT HI TECH PHARMA 2% N40014 001 JUL 10, 1995

LINDANE

LOTION; TOPICAL
SCABENE
AT STIEFEL 1% N86769 001
@ 1% N86769 001

SHAMPOO; TOPICAL
SCABENE
AT STIEFEL 1% N87940 001 APR 08, 1983
@ 1% N87940 001 APR 08, 1983

LISINOPRIL

TABLET; ORAL
PRINIVIL
AB MERCK 2.5MG N19558 006 JAN 28, 1994

> DLT >
> ADD >

LISINOPRIL

TABLET; ORAL
PRINIVIL
MERCK 2.5MG N19558 006 JAN 28, 1994

ZESTRIL
AB ZENECA 2.5MG N19777 005 APR 29, 1993
@ 2.5MG N19777 005 APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL
LITHOTABS
AB SOLVAY 300MG N16980 001
AB \+ 300MG N16980 001

TABLET, EXTENDED RELEASE; ORAL
LITHOBID
@ SOLVAY 300MG N18027 001
300MG N18027 001

LOSARTAN POTASSIUM

TABLET; ORAL
COZAAR
MERCK 25MG N20386 001 APR 14, 1995
\+ 50MG N20386 002 APR 14, 1995

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION
PHYSIOLYTE IN PLASTIC CONTAINER
AT MCGAW 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19024 001 JUN 08, 1984
30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19024 001 JUN 08, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

	PHYSIOSOL IN PLASTIC CONTAINER			
AT	ABBOTT	**30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML**	**N17637 002**	JUL 08, 1982
		30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N17637 002	JUL 08, 1982
	SYNOVALYTE IN PLASTIC CONTAINER			
AT	BAXTER	**30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML**	**N19326 001**	JAN 25, 1985
@		30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N19326 001	JAN 25, 1985

MAGNESIUM SULFATE

INJECTABLE; INJECTION

	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
	ABBOTT	1GM/100ML	N20488 001	JUL 11, 1995
+		2GM/100ML	N20488 002	JUL 11, 1995

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 10%				
AP	ABBOTT	**10GM/100ML**	**N16269 002**		
@		10GM/100ML	N16269 002		
	MANNITOL 15%				
AP	ABBOTT	**15GM/100ML**	**N16269 003**		
@		15GM/100ML	N16269 003		
	MANNITOL 20%				
AP	ABBOTT	**20GM/100ML**	**N16269 004**		
@		20GM/100ML	N16269 004	> ADD >	
	MANNITOL 25%			> ADD >	
AP	ABBOTT	**12.5GM/50ML**	**N16269 005**	> ADD >	
AP		**12.5GM/50ML**	**N16269 006**	> ADD >	
				AUG 25, 1994	> DLT >
@		12.5GM/50ML	N16269 005	> DLT >	
	MANNITOL 5%			> DLT >	
AP	ABBOTT	**5GM/100ML**	**N16269 001**	> DLT >	

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 5%		
@	ABBOTT	5GM/100ML	N16269 001

MASOPROCOL

CREAM; TOPICAL

	ACTINEX			
+	BLOCK DRUG	10%	N19940 001	SEP 04, 1992
+	SPKU	10%	N19940 001	SEP 04, 1992

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	MEBENDAZOLE			
AB	COPLEY PHARM	**100MG**	**N73580 001**	JAN 04, 1995
	VERMOX			
AB +	JANSSEN	**100MG**	**N17481 001**	

MEGESTROL ACETATE

TABLET; ORAL

	MEGACE			
AB	BRISTOL MYERS SQUIBB	**20MG**	**N16979 001**	
AB +		**40MG**	**N16979 002**	
AB	MEAD JOHNSON	**20MG**	**N16979 001**	
AB +		**40MG**	**N16979 002**	

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	METAPROTERENOL SULFATE			
AN	BARRE	**0.4%**	**N71855 001**	JUL 14, 1988
AN		**0.6%**	**N71726 001**	JUL 14, 1988
AN	PACO	**0.4%**	**N71855 001**	JUL 14, 1988
AN		**0.6%**	**N71726 001**	JUL 14, 1988

METAPROTERENOL SULFATE

SYRUP; ORAL

	ALUPENT			
AA	BOEHRINGER INGELHEIM	10MG/5ML	N17571 001	
AA	+	10MG/5ML	N17571 001	

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE			
	BRISTOL MYERS SQUIBB	500MG	N20357 001	DEC 29, 1994
	+	850MG	N20357 002	DEC 29, 1994
	LIPHA	500MG	N20357 001	DEC 29, 1994
	+	850MG	N20357 002	DEC 29, 1994

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING

METHADONE HCL			
MALLINCKRODT	50GM/BOT	N06383 002	
	100GM/BOT	N06383 003	
	500GM/BOT	N06383 004	

TABLET, DISPERSIBLE; ORAL

	METHADONE HCL			
AA	ROXANE	40MG	N74081 001	APR 28, 1995

METHOTRIMEPRAZINE

INJECTABLE; INJECTION

	LEVOPROME			
+	IMMUNEX	20MG/ML	N15865 001	
+	LEDERLE	20MG/ML	N15865 001	

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	METHYLDOPATE HCL			
AP	DUPONT MERCK	50MG/ML	N70691 001	JUN 19, 1987

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	METHYLDOPATE HCL			
AP	DUPONT MERCK	50MG/ML	N70849 001	JUN 19, 1987
AP	FAULDING	50MG/ML	N70691 001	JUN 19, 1987
AP		50MG/ML	N70849 001	JUN 19, 1987

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

	METHYLPREDNISOLONE ACETATE			
BP	AKORN	40MG/ML	N86903 001	OCT 20, 1982
BP		80MG/ML	N86903 002	OCT 20, 1982
	@	40MG/ML	N86903 001	OCT 20, 1982
	@	80MG/ML	N86903 002	OCT 20, 1982

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL			
AP	DUPONT MERCK	EQ 10MG BASE/2ML	N70847 001	NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001	MAR 03, 1989
AP	FAULDING	EQ 10MG BASE/2ML	N70847 001	NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001	MAR 03, 1989

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL

	LOPRESSOR			
	GEIGY	EQ 100MG TARTRATE	N19786 001	DEC 27, 1989
		EQ 200MG TARTRATE	N19786 002	DEC 27, 1989

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL

	LOPRESSOR			
	GEIGY	EQ 300MG TARTRATE	N19786 003	DEC 27, 1989
+		EQ 400MG TARTRATE	N19786 004	DEC 27, 1989
@		EQ 100MG TARTRATE	N19786 001	DEC 27, 1989
@		EQ 200MG TARTRATE	N19786 002	DEC 27, 1989
@		EQ 300MG TARTRATE	N19786 003	DEC 27, 1989
@		EQ 400MG TARTRATE	N19786 004	DEC 27, 1989

METOPROLOL TARTRATE

TABLET; ORAL

	METOPROLOL TARTRATE			
AB	LEMMON	**50MG**	**N74141 001**	JAN 31, 1995
AB		**100MG**	**N74141 002**	JAN 31, 1995
AB	PAR PHARM	**50MG**	**N74453 001**	APR 27, 1995
AB		**100MG**	**N74453 002**	APR 27, 1995

METRONIDAZOLE

CAPSULE; ORAL

	FLAGYL			
+	SEARLE	375MG	N20334 001	MAY 03, 1995

METYRAPONE

TABLET; ORAL

	METOPIRONE			
+	CIBA	250MG	N12911 001	
@		250MG	N12911 001	

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

	MEXILETINE HCL			
AB	NOVOPHARM	**150MG**	**N74377 001**	MAY 16, 1995
AB		**200MG**	**N74377 002**	MAY 16, 1995
AB		**250MG**	**N74377 003**	MAY 16, 1995
	MEXITIL			
AB	BOEHRINGER INGELHEIM	**150MG**	**N18873 002**	DEC 30, 1985
AB		**200MG**	**N18873 003**	DEC 30, 1985
AB	+	**250MG**	**N18873 004**	DEC 30, 1985

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

	MICONAZOLE NITRATE			
AB	ABLE	**200MG**	**N73508 001**	NOV 19, 1993
AB	NMC	**200MG**	**N73508 001**	NOV 19, 1993

MITOMYCIN

INJECTABLE; INJECTION

	MITOMYCIN			
AP	CETUS BEN VENUE	**5MG/VIAL**	**N64117 001**	APR 19, 1995
		20MG/VIAL	N64117 002	APR 19, 1995

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

	UNIVASC			
	SPKU	7.5MG	N20312 001	APR 19, 1995
+		15MG	N20312 002	APR 19, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL
CELLCEPT
\+ SYNTEX — 250MG — N50722 001 MAY 03, 1995

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001
AP		EQ 500MG BASE/VIAL	N62527 001 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N61984 002
AP		EQ 1GM BASE/VIAL	N62527 002 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62732 001 DEC 23, 1986
AP		EQ 2GM BASE/VIAL	N61984 003
AP		EQ 2GM BASE/VIAL	N62527 003 AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62732 002 DEC 23, 1986
AP		EQ 4GM BASE/VIAL	N61984 005
AP		EQ 10GM BASE/VIAL	N62527 004 AUG 02, 1984

NAFCILLIN SODIUM

AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001
AP		EQ 500MG BASE/VIAL	N62527 001 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N61984 002
AP		EQ 1GM BASE/VIAL	N62527 002 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62732 001 DEC 23, 1986
AP		EQ 2GM BASE/VIAL	N61984 003
AP		EQ 2GM BASE/VIAL	N62527 003 AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62732 002 DEC 23, 1986
AP		EQ 4GM BASE/VIAL	N61984 005
AP		EQ 10GM BASE/VIAL	N62527 004 AUG 02, 1984

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX

	OHMEDA	EQ 0.1MG BASE/ML	N20459 001 APR 17, 1995
\+		EQ 1MG BASE/ML	N20459 002 APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	FUJISAWA	0.02MG/ML	N70648 001 NOV 17, 1986
AP		0.4MG/ML	N70649 001 NOV 17, 1986
@		0.02MG/ML	N70648 001 NOV 17, 1986
@		0.4MG/ML	N70649 001 NOV 17, 1986

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AO	AKORN	100MG/ML	N87519 001 SEP 28, 1983
@		100MG/ML	N87519 001 SEP 28, 1983

NAPROXEN

TABLET; ORAL
NAPROXEN

AB	CHELSEA LABS	250MG	N74457 001 MAY 31, 1995
AB		375MG	N74457 002 MAY 31, 1995
AB		500MG	N74457 003 MAY 31, 1995
AB	DANBURY PHARMA	250MG	N74163 001 FEB 10, 1995
AB		375MG	N74163 002 FEB 10, 1995

NAPROXEN

TABLET; ORAL

	NAPROXEN			
AB	DANBURY PHARMA	**500MG**	**N74163 003**	FEB 10, 1995
AB	MOVA	**250MG**	**N74410 001**	APR 28, 1995
AB		**375MG**	**N74410 002**	APR 28, 1995
AB		**500MG**	**N74410 003**	APR 28, 1995
AB	ZENITH LABS	**250MG**	**N74111 001**	FEB 28, 1995
AB		**375MG**	**N74111 002**	FEB 28, 1995
AB		**500MG**	**N74111 003**	FEB 28, 1995

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	CHELSEA LABS	**EQ 250MG BASE**	**N74455 001**	MAY 31, 1995
AB		**EQ 500MG BASE**	**N74455 002**	MAY 31, 1995
AB	PUREPAC PHARM	**EQ 250MG BASE**	**N74319 001**	MAR 20, 1995
AB		**EQ 500MG BASE**	**N74319 002**	MAR 20, 1995
AB	ZENITH LABS	**EQ 250MG BASE**	**N74230 001**	MAR 14, 1995
AB		**EQ 500MG BASE**	**N74230 002**	MAR 14, 1995

NEOMYCIN SULFATE

TABLET; ORAL

	NEOMYCIN SULFATE			
AA	BIOCRAFT	**EQ 350MG BASE**	**N60304 001**	
		EQ 350MG BASE	N60304 001	
AA	LILLY @	**EQ 350MG BASE**	**N60385 001**	
		EQ 350MG BASE	N60385 001	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

		HABITROL			
BC	+	BASEL PHARMS	7MG/24HR	N20076 001	NOV 27, 1991
BC	+		14MG/24HR	N20076 002	NOV 27, 1991
BC	+		21MG/24HR	N20076 003	NOV 27, 1991
BC	+	CIBA	7MG/24HR	N20076 001	NOV 27, 1991
BC	+		14MG/24HR	N20076 002	NOV 27, 1991
BC	+		21MG/24HR	N20076 003	NOV 27, 1991

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

		NICORETTE			
	+	MERRELL DOW	EQ 2MG BASE	N18612 001	JAN 13, 1984
	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 001	JAN 13, 1984
		NICORETTE DS			
	+	MERRELL DOW	EQ 4MG BASE	N20066 001	JUN 08, 1992
	+	SMITHKLINE BEECHAM	EQ 4MG BASE	N20066 001	JUN 08, 1992

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

		NISOCOR			
	+	BAYER	10MG	N20356 001	FEB 02, 1995
	+		20MG	N20356 002	FEB 02, 1995
	+		30MG	N20356 003	FEB 02, 1995
	+		40MG	N20356 004	FEB 02, 1995
	+	ZENECA	10MG	N20356 001	FEB 02, 1995
	+		20MG	N20356 002	FEB 02, 1995

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

	NISOCOR			
+	ZENECA	30MG		N20356 003
				FEB 02, 1995
+		40MG		N20356 004
				FEB 02, 1995

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

	NITROFURANTOIN			
AB	GENEVA PHARMS	**25MG**		**N74336 001**
				JAN 25, 1995
AB		**50MG**		**N74336 002**
				JAN 25, 1995
AB		**100MG**		**N74336 003**
				JAN 25, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	NITRO-DUR			
+	KEY PHARMS	0.1MG/HR		N20145 001
				APR 04, 1995
+		0.2MG/HR		N20145 002
				APR 04, 1995
+		0.3MG/HR		N20145 003
				APR 04, 1995
+		0.4MG/HR		N20145 004
				APR 04, 1995
+		0.6MG/HR		N20145 005
				APR 04, 1995
+		0.8MG/HR		N20145 006
				APR 04, 1995

INJECTABLE; INJECTION

	NITROGLYCERIN			
AP	FUJISAWA	**5MG/ML**		**N70077 001**
				DEC 13, 1985
	@	5MG/ML		N70077 001
				DEC 13, 1985
	NITROSTAT			
AP	PARKE DAVIS	**5MG/ML**		**N18588 002**
				DEC 23, 1983
+		0.8MG/ML		N18588 001

NITROGLYCERIN

INJECTABLE; INJECTION

	NITROSTAT			
	@ PARKE DAVIS	0.8MG/ML		N18588 001
	@	5MG/ML		N18588 002
				DEC 23, 1983
	TRIDIL			
AP	DUPONT MERCK	**5MG/ML**		**N18537 001**
+		0.5MG/ML		N18537 002
				JUN 16, 1983
AP	FAULDING	**5MG/ML**		**N18537 001**
+		0.5MG/ML		N18537 002
				JUN 16, 1983

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL			
AB	LEMMON	**EQ 10MG BASE**		**N74132 001**
				MAR 27, 1995
AB		**EQ 25MG BASE**		**N74132 002**
				MAR 27, 1995
AB		**EQ 50MG BASE**		**N74132 003**
				MAR 27, 1995
AB		**EQ 75MG BASE**		**N74132 004**
				MAR 27, 1995

NYSTATIN

TABLET; ORAL

	MYCOSTATIN			
AA +	APOTHECON	**500,000 UNITS**		**N60574 001**
AA +	SQUIBB	**500,000 UNITS**		**N60574 001**

TABLET; VAGINAL

	NYSTATIN			
AT	LEMMON	**100,000 UNITS**		**N62502 001**
				DEC 23, 1983
	@	100,000 UNITS		N62502 001
				DEC 23, 1983

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	PHARMAFAIR	**100,000 UNITS/GM;0.1%**	**N62656 001**	**JUL 30, 1986**
	@	100,000 UNITS/GM;0.1%	N62656 001	JUL 30, 1986

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

	ZOFRAN IN PLASTIC CONTAINER			
	+ GLAXO	EQ 0.64MG BASE/ML	N20403 001	JAN 31, 1995

OXACILLIN SODIUM

CAPSULE; ORAL

	OXACILLIN SODIUM			
AB	APOTHECON	**EQ 250MG BASE**	**N61450 002**	
AB	+	**EQ 500MG BASE**	**N61450 001**	
	PROSTAPHLIN			
AB	APOTHECON	**EQ 250MG BASE**	**N61450 002**	
AB	+	**EQ 500MG BASE**	**N61450 001**	

POWDER FOR RECONSTITUTION; ORAL

	OXACILLIN SODIUM			
AA	APOTHECON	**EQ 250MG BASE/5ML**	**N61457 001**	
	PROSTAPHLIN			
AA	APOTHECON	**EQ 250MG BASE/5ML**	**N61457 001**	

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

	DARICON			
	+ PFIZER	10MG	N11612 001	
	@	10MG	N11612 001	

PENBUTOLOL SULFATE

TABLET; ORAL

	LEVATOL			
	@ REED AND CARNRICK	10MG	N18976 001	DEC 30, 1987

PENBUTOLOL SULFATE

TABLET; ORAL

	LEVATOL			
	+ REED AND CARNRICK	20MG	N18976 004	JAN 05, 1989
	@ SPKU	10MG	N18976 001	DEC 30, 1987
	+	20MG	N18976 004	JAN 05, 1989

PENICILLAMINE

TABLET; ORAL

	DEPEN			
	+ WALLACE	250MG	N19854 001	
	DEPEN 250			
	+ WALLACE	250MG	N19854 001	

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
	@ CONSOLIDATED PHARM	500,000 UNITS/VIAL	N60806 001	
	@	1,000,000 UNITS/VIAL	N60806 002	
	@	5,000,000 UNITS/VIAL	N60806 003	
	@	10,000,000 UNITS/VIAL	N60806 004	
	@ COPANOS	500,000 UNITS/VIAL	N60806 001	
	@	1,000,000 UNITS/VIAL	N60806 002	
	@	5,000,000 UNITS/VIAL	N60806 003	
	@	10,000,000 UNITS/VIAL	N60806 004	
AP	+ LILLY	**1,000,000 UNITS/VIAL**	**N60384 002**	
AP	+	**5,000,000 UNITS/VIAL**	**N60384 001**	
AP	+	**20,000,000 UNITS/VIAL**	**N60384 005**	
AP		**20,000,000 UNITS/VIAL**	**N60601 001**	
	+	200,000 UNITS/VIAL	N60384 004	
	+	500,000 UNITS/VIAL	N60384 003	
	@	200,000 UNITS/VIAL	N60384 004	
	@	500,000 UNITS/VIAL	N60384 003	
	@	1,000,000 UNITS/VIAL	N60384 002	
	@	5,000,000 UNITS/VIAL	N60384 001	
	@	20,000,000 UNITS/VIAL	N60384 005	
	@	20,000,000 UNITS/VIAL	N60601 001	
	PFIZERPEN			
AP	PFIZER	**1,000,000 UNITS/VIAL**	**N60657 001**	
AP	+	**1,000,000 UNITS/VIAL**	**N60657 001**	
AP		**5,000,000 UNITS/VIAL**	**N60657 002**	

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PFIZERPEN				
AP	+ PFIZER	5,000,000 UNITS/VIAL	N60657 002		
AP		20,000,000 UNITS/VIAL	N60657 003		
AP	+	20,000,000 UNITS/VIAL	N60657 003		

TABLET; ORAL

	PENICILLIN G POTASSIUM				
AB	DISTA	250,000 UNITS	N60403 001	> ADD >	
	@ LILLY	250,000 UNITS	N60403 001	> ADD >	

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	PENICILLIN G PROCAINE		
	@ CONSOLIDATED PHARM	300,000 UNITS/ML	N60800 001
	@	600,000 UNITS/1.2ML	N60800 002
	@ COPANOS	300,000 UNITS/ML	N60800 001
	@	600,000 UNITS/1.2ML	N60800 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	PENICILLIN V POTASSIUM		
AA	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61529 001
AA		EQ 250MG BASE/5ML	N61529 002
AA	COPANOS	EQ 125MG BASE/5ML	N61529 001
AA		EQ 250MG BASE/5ML	N61529 002

TABLET; ORAL

	BETAPEN-VK		
AB	APOTHECON	EQ 250MG BASE	N61411 001
AB		EQ 500MG BASE	N61411 002
	PENICILLIN V POTASSIUM		
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61528 001
AB		EQ 500MG BASE	N61528 002
AB	COPANOS	EQ 250MG BASE	N61528 001
AB		EQ 500MG BASE	N61528 002
	VEETIDS		
AB	APOTHECON	EQ 250MG BASE	N61411 001
AB		EQ 500MG BASE	N61411 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

	PENTACARINAT			
AP	ARMOUR	300MG/VIAL	N73447 001	APR 28, 1994
AP	RHONE POULENC RORER	300MG/VIAL	N73447 001	APR 28, 1994
	PENTAMIDINE ISETHIONATE			
AP	STERIS	300MG/VIAL	N74303 001	AUG 17, 1995

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON			
	AMARIC	2MG	N20184 001	DEC 30, 1993
		4MG	N20184 002	DEC 30, 1993
	+	8MG	N20184 003	DEC 30, 1993
	JOHNSON RW	2MG	N20184 001	DEC 30, 1993
		4MG	N20184 002	DEC 30, 1993
	+	8MG	N20184 003	DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	MELFIAT-105		
	@ NUMARK	105MG	N87487 001 OCT 13, 1982
	@ SOLVAY	105MG	N87487 001 OCT 13, 1982
	SPRX-105		
	@ NUMARK	105MG	N88024 001 DEC 22, 1982
	@ SOLVAY	105MG	N88024 001 DEC 22, 1982

TABLET; ORAL

	MELFIAT		
	@ NUMARK	35MG	N83790 002
	@ SOLVAY	35MG	N83790 002

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

@	NUMARK	35MG	N83790 001
@	SOLVAY	35MG	N83790 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	LEMMON	**30MG**	**N87777 001** **NOV 01, 1985**
@		30MG	N87777 001 NOV 01, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN

	FISONS	EQ 15MG BASE	N11613 004
+		EQ 30MG BASE	N11613 002

IONAMIN-15

	FISONS	EQ 15MG BASE	N11613 004

IONAMIN-30

+	FISONS	EQ 30MG BASE	N11613 002

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC

+	LEO PHARM	12.5MG	N19456 001 DEC 28, 1989
+		25MG	N19456 002 DEC 28, 1989
@		12.5MG	N19456 001 DEC 28, 1989
@		25MG	N19456 002 DEC 28, 1989

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	ROYCE LABS	**5MG**	**N74437 001** FEB 27, 1995

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	ROYCE LABS	**10MG**	**N74437 002** FEB 27, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL
NULYTELY-FLAVORED

	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT	N19797 002 NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
GOLYTELY

AA	BRAINTREE	**227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET**	**N19011 002** JUN 02, 1992

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIZIDE

	PFIZER	0.5MG;1MG	N17986 001
		0.5MG;2MG	N17986 002
+		0.5MG;5MG	N17986 003
		0.5MG;EQ 1MG BASE	N17986 001
		0.5MG;EQ 2MG BASE	N17986 002
+		0.5MG;EQ 5MG BASE	N17986 003

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	AKORN	**2MEQ/ML**	**N88286 001** **SEP 05, 1985**
@		2MEQ/ML	N88286 001 SEP 05, 1985

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		KAON CL			
		SAVAGE LABS	6.7MEQ	N17046 001	
		@	6.7MEQ	N17046 001	
		KAON CL-10			
	BC	SAVAGE LABS	10MEQ	N17046 002	
		@	10MEQ	N17046 002	

PREDNISOLONE

TABLET; ORAL

		CORTALONE			
>_DLT_>	BX	HALSEY	1MG	N80304 003	
>_DLT_>	BX		2.5MG	N80304 002	
>_DLT_>	BX		5MG	N80304 001	
>_ADD_>		@	1MG	N80304 003	
>_ADD_>		@	2.5MG	N80304 002	
>_ADD_>		@	5MG	N80304 001	
		PREDNISOLONE			
>_DLT_>	BX	SPERTI	1MG	N80358 001	
>_ADD_>			1MG	N80358 001	

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

		ECONOPRED PLUS			
AB		ALCON	1%	N17469 001	
BX			1%	N17469 001	

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

		HYDELTRASOL			
AP	+	MERCK SHARP DOHME	EQ 20MG PHOSPHATE/ML	N11583 002	
	+		EQ 20MG PHOSPHATE/ML	N11583 002	
		PREDNISOLONE SODIUM PHOSPHATE			
AP		STERIS	EQ 20MG PHOSPHATE/ML	N80517 001	
		@	EQ 20MG PHOSPHATE/ML	N80517 001	

PREDNISONE

TABLET; ORAL

		CORTAN			
>_DLT_>	BX	HALSEY	20MG	N87480 001	

PREDNISONE

TABLET; ORAL

		CORTAN			
>_DLT_>		@ HALSEY	20MG	N87480 001	
>_ADD_>					

PROCAINAMIDE HYDROCHLORIDE

TABLET; ORAL

		PRONESTYL			
		APOTHECON	250MG	N17371 001	
			375MG	N17371 002	
	+		500MG	N17371 003	
		SQUIBB	250MG	N17371 001	
			375MG	N17371 002	
	+		500MG	N17371 003	

TABLET, EXTENDED RELEASE; ORAL

		PROCAN SR			
AB		PARKE DAVIS	250MG	N86468 001	
		@	250MG	N86468 001	
		PRONESTYL-SR			
BC		APOTHECON	500MG	N87361 001	
BC		BRISTOL MYERS SQUIBB	500MG	N87361 001	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		PROMETHAZINE HCL			
AP		AKORN	25MG/ML	N83955 002	
AP			50MG/ML	N83955 001	
		@	25MG/ML	N83955 002	
		@	50MG/ML	N83955 001	

PROPANTHELINE BROMIDE

TABLET; ORAL

		PROPANTHELINE BROMIDE			
AA		DANBURY PHARMA	15MG	N83029 002	
		@	15MG	N83029 002	
AA		GLOBAL PHARMS	15MG	N84541 002	
		@	15MG	N84541 002	
AA		TABLICAPS	15MG	N84428 001	
		@	15MG	N84428 001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		OPHTHAINE			
AT	+	APOTHECON	0.5%	N08883 001	
AT	+	SQUIBB	0.5%	N08883 001	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL			
AB	PARKE DAVIS	20MG	N70439 001	
			SEP 15, 1986	
AB		40MG	N70440 001	
			SEP 15, 1986	
AB		60MG	N70441 001	
			SEP 24, 1986	
AB		80MG	N70442 001	
			SEP 15, 1986	
AB	WARNER CHILCOTT	10MG	N70438 001	
			SEP 15, 1986	
	@	10MG	N70438 001	
			SEP 15, 1986	
	@	20MG	N70439 001	
			SEP 15, 1986	
	@	40MG	N70440 001	
			SEP 15, 1986	
	@	60MG	N70441 001	
			SEP 24, 1986	
	@	80MG	N70442 001	
			SEP 15, 1986	

PROPYLTHIOURACIL

TABLET; ORAL

	PROPYLTHIOURACIL			
BD	LILLY	50MG	N06213 001	
	@	50MG	N06213 001	

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

		PROTRIPTYLINE HCL			
> ADD >					
> ADD >	AB	SIDMAK LABS NJ	5MG	N73644 001	
> ADD >				AUG 24, 1995	

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

		PROTRIPTYLINE HCL			
> ADD >					
> ADD >	AB	SIDMAK LABS NJ	10MG	N73645 001	
> ADD >				AUG 24, 1995	
		VIVACTIL			
> ADD >	AB	MERCK SHARP DOHME	5MG	N16012 001	
> ADD >	AB	+	10MG	N16012 002	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PYRIDOXINE HCL			
AP	AKORN	100MG/ML	N87967 001	
			OCT 01, 1982	
	@	100MG/ML	N87967 001	
			OCT 01, 1982	

QUINESTROL

TABLET; ORAL

	ESTROVIS			
	+ PARKE DAVIS	0.1MG	N16768 002	
	@	0.1MG	N16768 002	

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

	QUINALAN			
BC	LANNETT	324MG	N88081 001	
			FEB 10, 1986	
	@	324MG	N88081 001	
			FEB 10, 1986	

QUINIDINE SULFATE

TABLET; ORAL

		QUINIDINE SULFATE			
> DLT >	AB	PHOENIX LABS NY	200MG	N83963 001	
> ADD >		@ VINTAGE PHARMS	200MG	N83963 001	

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUWOLFIA SERPENTINA

> DLT >	BP	HALSEY	50MG	N80498 001	> ADD >
> DLT >	BP		100MG	N80498 002	> ADD >
> ADD >	@		50MG	N80498 001	> ADD >
> ADD >	@		100MG	N80498 002	> ADD >

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM

AA	**ZENITH LABS**	**100MG**	**N85869 001**	
@		100MG	N85869 001	

SEVOFLURANE

LIQUID; INHALATION
ULTANE

	ABBOTT	100%	N20478 001 JUN 07, 1995

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**BAXTER**	**9MG/ML**	**N16677 004** **OCT 30, 1985**	
AP	+	**9MG/ML**	**N16677 004** OCT 30, 1985	

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT	**BAXTER**	**450MG/100ML**	**N18497 001** **FEB 19, 1982**	
@		450MG/100ML	N18497 001 FEB 19, 1982	

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
BIO-TROPIN

+	BIO TECH GEN	4.8MG/VIAL	N19774 001 MAY 25, 1995	

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
GENOTROPIN

+	PHARMACIA	1.5MG/VIAL	N20280 004 AUG 24, 1995	
+		5.8MG/VIAL	N20280 006 AUG 24, 1995	

NORDITROPIN

+	NOVO NORDISK	4MG/VIAL	N19721 001 MAY 08, 1995	
+		8MG/VIAL	N19721 002 MAY 08, 1995	

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
BERLEX

		120MG	**N19865 005** **APR 20, 1994**
@		120MG	N19865 005 APR 20, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

AP	**LILLY**	**EQ 1GM BASE/VIAL**	**N60107 001**	
AP		**EQ 5GM BASE/VIAL**	**N60107 002**	
@		EQ 1GM BASE/2ML	N60404 001	
@		EQ 1GM BASE/2ML	N60404 001	
@		EQ 1GM BASE/VIAL	N60107 001	
@		EQ 5GM BASE/VIAL	N60107 002	
AP	+ **PFIZER**	**EQ 1GM BASE/VIAL**	**N60076 001**	
AP	+	**EQ 5GM BASE/VIAL**	**N60076 002**	
+		EQ 1GM BASE/VIAL	N60076 001	
+		EQ 5GM BASE/VIAL	N60076 002	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN

AP	**APOTHECON**	**20MG/ML**	**N08847 001**	
@		100MG/ML	N08847 003	
AP	**SQUIBB**	**20MG/ML**	**N08847 001**	
@		100MG/ML	N08847 003	

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

	TRIMETH/SULFA			
AB	BARRE	200MG/5ML;40MG/5ML	N72289 001	MAY 23, 1988
	@	200MG/5ML;40MG/5ML	N72289 001	MAY 23, 1988

SULFUR

POWDER; TOPICAL

	BENSULFOID		
	@ POYTHRESS	33.32%	N02918 001

SUMATRIPTAN SUCCINATE

TABLET; ORAL

	IMITREX			
	GLAXO WELLCOME	EQ 25MG BASE	N20132 002	JUN 01, 1995
	+	EQ 50MG BASE	N20132 003	JUN 01, 1995
	@	EQ 100MG BASE	N20132 001	JUN 01, 1995

> ADD >

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

	TECHNELITE		
	DUPONT	0.0083-2.7 CI/GENERATOR	N17771 001
	TECHNETIUM TC 99M GENERATOR		
	DUPONT	0.0083-2.7 CI/GENERATOR	N17771 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL			
AB	PVT FORM	250MG	N62686 001	JUL 24, 1986
AB		500MG	N62686 002	JUL 24, 1986
	@	250MG	N62686 001	JUL 24, 1986

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL			
	@ PVT FORM	500MG	N62686 002	JUL 24, 1986

FIBER, EXTENDED RELEASE; PERIODONTAL

	ACTISITE			
	+ ON SITE	12.7MG/FIBER	N50653 001	MAR 25, 1994
	+ ON SITE ALZA	12.7MG/FIBER	N50653 001	MAR 25, 1994

OINTMENT; OPHTHALMIC

	ACHROMYCIN		
	+ LEDERLE	10MG/GM	N50266 001
	@ STORZ OPHTHALM	10MG/GM	N50266 001

SUSPENSION; ORAL

	ACHROMYCIN V		
AB	+ LEDERLE	125MG/5ML	N50263 002
	SUMYCIN		
AB	APOTHECON	125MG/5ML	N60400 001
	TETRACYCLINE HCL		
AB	BARRE	125MG/5ML	N60633 001
AB	MK LABS	125MG/5ML	N60174 001
	@ PROTER	125MG/5ML	N60446 001
AB	PUREPAC PHARM	125MG/5ML	N60291 001
	TETRACYN		
AB	PFIPHARMECS	125MG/5ML	N60095 001
	TETRAMED		
AB	ZENITH LABS	125MG/5ML	N61468 001

SUSPENSION/DROPS; OPHTHALMIC

	ACHROMYCIN		
	+ LEDERLE	1%	N50268 001
	@ STORZ OPHTHALM	1%	N50268 001

SYRUP; ORAL

	ACHROMYCIN V		
AB	+ LEDERLE	125MG/5ML	N50263 002
	SUMYCIN		
AB	SQUIBB	125MG/5ML	N60400 001
	TETRACYCLINE HCL		
AB	BARRE	125MG/5ML	N60633 001
AB	MK LABS	125MG/5ML	N60174 001
AB	PUREPAC PHARM	125MG/5ML	N60291 001
	TETRACYN		
AB	PFIPHARMECS	125MG/5ML	N60095 001

TETRACYCLINE HYDROCHLORIDE

SYRUP; ORAL

		TETRAMED		
AB		ZENITH LABS	**125MG/5ML**	**N61468 001**

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

		THEOPHYLLINE		
BC		FAULDING	100MG	N89976 001 JAN 04, 1995
BC			200MG	N89977 001 JAN 04, 1995
BC			300MG	N89932 001 JAN 04, 1995

TABLET, EXTENDED RELEASE; ORAL

		LABID		
BC	+	PROCTER AND GAMBLE	250MG	N87225 001
	@		250MG	N87225 001
		THEOLAIR-SR		
BC		3M	250MG	N86363 002 JUL 16, 1987
			250MG	N86363 002 JUL 16, 1987
		THEOPHYLLINE		
AB		INWOOD LABS	**450MG**	**N40034 001** APR 28, 1995
		UNI-DUR		
BC	+	KEY PHARMS	400MG	N89822 001 JAN 04, 1995
	+		600MG	N89823 001 JAN 04, 1995
		UNIPHYL		
BC		PURDUE FREDERICK	400MG	N87571 001 SEP 01, 1982

THEOPHYLLINE SODIUM GLYCINATE

TABLET; ORAL

> DLT >		ASBRON		
> DLT >	+	DORSEY	EQ 150MG BASE	N85148 001
> ADD >	@	SANDOZ	EQ 150MG BASE	N85148 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		THIAMINE HCL		
AP		AKORN	**100MG/ML**	**N87968 001** OCT 01, 1982
	@		100MG/ML	N87968 001 OCT 01, 1982

THIOTEPA

INJECTABLE; INJECTION

		THIOPLEX		
		IMMUNEX	15MG/VIAL	N20058 001 DEC 22, 1994
AP		LEDERLE	**15MG/VIAL**	**N20058 001** DEC 22, 1994
		THIOTEPA		
AP	+	IMMUNEX	**15MG/VIAL**	**N11683 001**
	+		15MG/VIAL	N11683 001

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

		BETIMOL		
	+	LEIRAS	EQ 0.25% BASE	N20439 001 MAR 31, 1995
	+		EQ 0.5% BASE	N20439 002 MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

		TIMOLOL MALEATE		
AT		ALCON	**EQ 0.25% BASE**	**N74261 001** APR 28, 1995
AT			**EQ 0.5% BASE**	**N74262 001** APR 28, 1995
		TIMOPTIC		
AT	+	MERCK	**EQ 0.25% BASE**	**N18086 001**
AT	+		**EQ 0.5% BASE**	**N18086 002**

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1
+ BRISTOL MYERS 6.5% N19355 001 DEC 30, 1986
+ BRISTOL MYERS SQUIBB 6.5% N19355 001 DEC 30, 1986

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL
TONOCARD
ASTRA MERCK 400MG N18257 001 NOV 09, 1984
+ 600MG N18257 002 NOV 09, 1984
MERCK SHARP DOHME 400MG N18257 001 NOV 09, 1984
+ 600MG N18257 002 NOV 09, 1984

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
ULTRAM
+ JOHNSON RW 50MG N20281 002 MAR 03, 1995
@ 100MG N20281 001 MAR 03, 1995

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
KENALOG-H
AT APOTHECON **0.1%** **N86240 001**
AT WESTWOOD SQUIBB **0.1%** **N86240 001**

INJECTABLE; INJECTION
KENALOG-10
+ APOTHECON 10MG/ML N12041 001
+ WESTWOOD SQUIBB 10MG/ML N12041 001
KENALOG-40
BP APOTHECON 40MG/ML N14901 001
BP WESTWOOD SQUIBB 40MG/ML N14901 001

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL
KENALOG
AT APOTHECON **0.025%** **N84343 001**
AT + **0.1%** **N84343 002**
@ 0.025% N11602 003
@ 0.1% N11602 001
AT WESTWOOD SQUIBB **0.025%** **N84343 001**
AT + **0.1%** **N84343 002**
@ 0.025% N11602 003
@ 0.1% N11602 001
TRIAMCINOLONE ACETONIDE
AT BARRE **0.025%** **N87191 001 SEP 08, 1982**
@ 0.025% N87191 001 SEP 08, 1982

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE IN ABSORBASE
+ CAROLINA MEDCL 0.05% N89595 001 MAR 23, 1995

PASTE; DENTAL
KENALOG IN ORABASE
AT + APOTHECON **0.1%** **N12097 001**
AT + SQUIBB **0.1%** **N12097 001**

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
ARISTOCORT
BP + LEDERLE 25MG/ML N11685 003
+ 25MG/ML N11685 003
TRIAMCINOLONE DIACETATE
BP AKORN 25MG/ML N85122 001
BP 40MG/ML N86394 001
@ 25MG/ML N85122 001
@ 40MG/ML N86394 001

TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUA
BP SCHERING 2MG N12265 001
@ 2MG N12265 001

TRILOSTANE

CAPSULE; ORAL
MODRASTANE

		SANOFI WINTHROP	30MG	N18719 002 DEC 31, 1984
	+		60MG	N18719 001 DEC 31, 1984
	@		30MG	N18719 002 DEC 31, 1984
	@		60MG	N18719 001 DEC 31, 1984

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL

		ASCENT	EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995

TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
TRIPROLIDINE HCL

	+	DANBURY PHARMA	2.5MG	N85094 001
	@		2.5MG	N85094 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL
TERFONYL

	+	SQUIBB	167MG/5ML;167MG/5ML; 167MG/5ML	N06904 002
	@		167MG/5ML;167MG/5ML; 167MG/5ML	N06904 002

TABLET; ORAL
SULFA-TRIPLE #2

AB		**GLOBAL PHARMS**	**167MG;167MG;167MG**	**N80079 001**
AB	+		**167MG;167MG;167MG**	**N80079 001**
		TERFONYL		
AB	+	SQUIBB	**167MG;167MG;167MG**	**N06904 001**
	@		167MG;167MG;167MG	N06904 001

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

AP	+	APOTHECON	**3MG/ML**	**N05657 001**
AP	+	SQUIBB	**3MG/ML**	**N05657 001**

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX

	+	BURROUGHS WELLCOME	EQ 500MG BASE	N20487 001 JUN 23, 1995
	@		EQ 1GM BASE	N20487 002 JUN 23, 1995

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID

AA		HIGH TECH PHARMA	**250MG/5ML**	**N74060 001** JAN 13, 1995

VANCOMYCIN HYDROCHLORIDE

POWDER FOR RECONSTITUTION; ORAL
VANCOCIN HCL

AA		LILLY	**EQ 250MG BASE/5ML**	**N61667 002** JUL 13, 1983
AA	+		**EQ 500MG BASE/6ML**	**N61667 001**
AB			**EQ 250MG BASE/5ML**	**N61667 002** JUL 13, 1983
	+		EQ 500MG BASE/6ML	N61667 001
		VANCOLED		
AA		LEDERLE	**EQ 250MG BASE/5ML**	**N63321 002** OCT 15, 1993
AA			**EQ 500MG BASE/6ML**	**N63321 003** OCT 15, 1993
AB			**EQ 250MG BASE/5ML**	**N63321 002** OCT 15, 1993
	@		EQ 500MG BASE/6ML	N63321 003 OCT 15, 1993

VECURONIUM BROMIDE

INJECTABLE; INJECTION

		NORCURON			
> ADD >	**AP**	+ ORGANON	**10MG/VIAL**	**N18776 002**	
> ADD >				APR 30, 1984	
> ADD >	**AP**	+	**20MG/VIAL**	**N18776 003**	
> ADD >				JAN 03, 1992	
> ADD >		**VECURONIUM BROMIDE**			
> ADD >	**AP**	STERIS	**10MG/VIAL**	**N74334 001**	
> ADD >				AUG 31, 1995	
> ADD >	**AP**		**20MG/VIAL**	**N74334 002**	
> ADD >				AUG 31, 1995	

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

	VERAPAMIL HCL			
AP	BEDFORD	**2.5MG/ML**	**N72888 001**	
			JUL 28, 1995	

VITAMIN A

CAPSULE; ORAL

	VITAMIN A			
AA	BANNER PHARMACAPS	**50,000 USP UNITS**	**N83973 001**	
@		50,000 USP UNITS	N83973 001	

VITAMIN A PALMITATE

CAPSULE; ORAL

	VITAMIN A			
AA	BANNER PHARMACAPS	**EQ 50,000 UNITS BASE**	**N80702 001**	
@		EQ 50,000 UNITS BASE	N80702 001	
	VITAMIN A PALMITATE			
AA	BANNER PHARMACAPS	**EQ 50,000 UNITS BASE**	**N83948 001**	
@		EQ 50,000 UNITS BASE	N83948 001	

WARFARIN SODIUM

INJECTABLE; INJECTION

	COUMADIN		
	+ DUPONT MERCK	5MG/VIAL	N09218 024
			FEB 07, 1995

WATER FOR INJECTION, STERILE

LIQUID; N/A

	BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER			
AP	FUJISAWA	**100%**	**N89099 001**	
			DEC 29, 1987	
AP		**100%**	**N89100 001**	
			DEC 29, 1987	
@		100%	N89099 001	
			DEC 29, 1987	
@		100%	N89100 001	
			DEC 29, 1987	

ACETAMINOPHEN

SUPPOSITORY; RECTAL
ACETAMINOPHEN

ABLE	120MG	N73106 001 FEB 27, 1995	>DLT<
	325MG	N73107 001 FEB 27, 1995	>DLT<
	650MG	N73108 001 FEB 27, 1995	>DLT<

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VASOCON-A

+ CIBA	0.5%;0.05%	N18746 002 JUL 11, 1994

CIMETIDINE

TABLET; ORAL
TAGAMET HB

+ SMITHKLINE BEECHAM	100MG	N20238 001 JUN 19, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
ANTITUSSIVE

PERRIGO	12.5MG/5ML	N71292 001 APR 10, 1987
@	12.5MG/5ML	N71292 001 APR 10, 1987

HYDRAMINE

BARRE	12.5MG/5ML	N70205 001 JAN 28, 1986
@	12.5MG/5ML	N70205 001 JAN 28, 1986

SILPHEN

SILARX	12.5MG/5ML	N72646 001 FEB 27, 1992
@	12.5MG/5ML	N72646 001 FEB 27, 1992

>DLT< >ADD< VICKS FORMULA 44

@ PROCTER AND GAMBLE	12.5MG/5ML	N70524 001 JAN 14, 1987 >ADD<

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
VICKS FORMULA 44

VICKS HLTH CARE	12.5MG/5ML	N70524 001 JAN 14, 1987 >DLT<

FAMOTIDINE

TABLET; ORAL
PEPCID AC

+ MERCK	10MG	N20325 001 APR 28, 1995

IBUPROFEN

CAPSULE; ORAL
MIDOL

+ WINTHROP	200MG	N70626 001 SEP 02, 1987
	200MG	N71002 001 SEP 02, 1987
@	200MG	N70626 001 SEP 02, 1987
@	200MG	N71002 001 SEP 02, 1987

PROVEL

+ SANDOZ	200MG	N20402 001 APR 20, 1995

SUSPENSION; ORAL
CHILDREN'S MOTRIN

+ MCNEIL CONS PRODS	100MG/5ML	N20516 001 JUN 16, 1995

TABLET; ORAL
MIDOL

WINTHROP	200MG	N70591 001 SEP 02, 1987
	200MG	N71001 001 SEP 02, 1987
@	200MG	N70591 001 SEP 02, 1987
@	200MG	N71001 001 SEP 02, 1987

INSULIN PORK

INJECTABLE; INJECTION
INSULIN
+ NOVO NORDISK 100 UNITS/ML N17926 003
REGULAR INSULIN
+ NOVO NORDISK 100 UNITS/ML N17926 003

INSULIN PURIFIED PORK

INJECTABLE; INJECTION
VELOSULIN
NOVO NORDISK 100 UNITS/ML N18193 001
@ 100 UNITS/ML N18193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN NORDISK MIXTARD (PORK)
+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N18195 001
@ 30 UNITS/ML;70 UNITS/ML N18195 001

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
MIXTARD HUMAN 70/30
+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19585 001
MAR 11, 1988
@ 30 UNITS/ML;70 UNITS/ML N19585 001
MAR 11, 1988
NOVOLIN 70/30
+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19441 001
JUL 11, 1986
@ 30 UNITS/ML;70 UNITS/ML N19441 001
JUL 11, 1986

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION
NPH ILETIN II
> DLT > + LILLY 100 UNITS/ML N18479 001
> ADD > @ 100 UNITS/ML N18479 001

> DLT >
> ADD >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN INSULATARD NPH NORDISK
+ NOVO NORDISK 100 UNITS/ML N18194 001
@ 100 UNITS/ML N18194 001
NPH ILETIN II (PORK)
@ LILLY 100 UNITS/ML N18345 001
+ 100 UNITS/ML N18345 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
INSULATARD NPH HUMAN
+ NOVO NORDISK 100 UNITS/ML N19449 001
MAY 30, 1986
@ 100 UNITS/ML N19449 001
MAY 30, 1986

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC AND ILETIN II
+ LILLY 100 UNITS/ML N18476 001
@ 100 UNITS/ML N18476 001
PROTAMINE ZINC INSULIN
SQUIBB 100 UNITS/ML N17928 003
+ 100 UNITS/ML N17928 003

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
LEMMON 1MG/5ML N73478 001
JUN 23, 1995

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE
LEMMON 2% N74136 001
JAN 04, 1995

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
ABLE 100MG N73507 001
NOV 19, 1993

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

NMC	100MG	N73507 001	
		NOV 19, 1993	

NAPROXEN SODIUM

TABLET; ORAL
ALEVE

HAMILTON PHARMS	EQ 200MG BASE	N20204 002	
		JAN 11, 1994	
+	EQ 200MG BASE	N20204 002	
		JAN 11, 1994	

NONOXYNOL-9

AEROSOL; VAGINAL
DELFEN

@ ORTHO	12.5%	N14349 002	

SPONGE; VAGINAL
TODAY

> DLT > @ WHITEHALL LABS	1GM	N18683 001	
> DLT >		APR 01, 1983	
> ADD > @ WHITEHALL ROBINS	1GM	N18683 001	
> ADD >		APR 01, 1983	

POTASSIUM IODIDE

SOLUTION; ORAL
POTASSIUM IODIDE

+ ROXANE	1GM/ML	N18551 001	
		FEB 19, 1982	
@	1GM/ML	N18551 001	
		FEB 19, 1982	

PYRITHIONE ZINC

LOTION; TOPICAL
HEAD & SHOULDERS CONDITIONER

+ PROCTER AND GAMBLE	0.3%	N19412 002	
		MAR 10, 1986	

PYRITHIONE ZINC

LOTION; TOPICAL
HEAD & SHOULDERS CONDITIONER

@ PROCTER AND GAMBLE	0.3%	N19412 002	
		MAR 10, 1986	

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 8 / AUG '95

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT 6GM/100ML;0.9GM/100ML N74193
JAN 30, 1995

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January - August, 1995]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ADENO-AS'TED VIRAL-BASED VECTOR CYSTIC FIBROSIS GENE THERAPY TN=	TREATMENT OF CYSTIC FIBROSIS.	TARGETED GENETICS CORPORATION 1100 OLIVE WAY, SUITE 100 SEATTLE WA 98101 DD 02/15/95 MA / /
ALGLUCERASE INJECTION TN= CEREDASE	REPLACEMENT THERAPY IN PATIENTS WITH TYPE II AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139-1562 DD 07/21/95 MA / /
AMINOCAPROIC ACID TN=	FOR THE TOPICAL TREATMENT OF TRAUMATIC HYPHEMA OF THE EYE.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 01/06/95 MA / /
APL 400-020 TN=	TREATMENT OF CUTANEOUS T CELL LYMPHOMA.	APOLLON, INC. ONE GREAT VALLEY PARKWAY MALVERN PA 19355 DD 03/08/95 MA / /
APOMORPHINE HCL TN=	TREATMENT OF ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	PENTECH PHARMACEUTICALS, INC. 417 HARVESTER COURT WHEELING IL 60090 DD 07/17/95 MA / /
CHONDROITINASE TN=	TREATMENT OF PATIENTS UNDERGOING VITRECTOMY.	STORZ OPHTHALMICS AMERICAN CYANAMID COMPANY PEARL RIVER NY 10965 DD 02/09/95 MA / /
CLOTRIMIDAZOLE TN=	TREATMENT OF SICKLE CELL DISEASE.	BRUGNARA, CARLO M.D. THE CHILDREN'S HOSPITAL BOSTON MA 02115 DD 04/24/95 MA / /
CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS) TN= ADgvCFTR.10	TREATMENT OF CYSTIC FIBROSIS.	GENVAC, INCORPORATED 12111 PARKLAWN DRIVE ROCKVILLE MD 20852 DD 03/09/95 MA / /
ENCAPSULATED PORCINE ISLET PREPARATION TN= BETARX	TREATMENT OF TYPE I DIABETIC PATIENTS WHO ARE ALREADY ON IMMUNOSUPPRESSION.	VIVORX 3212 NEBRASKA AVENUE SANTA MONICA CA 90404 DD 07/05/95 MA / /
FIBRINOGEN (HUMAN) TN=	FOR THE CONTROL OF BLEEDING AND PROPHYLACTIC TREATMENT OF PATIENTS DEFICIENT IN FIBRINOGEN.	ALPHA THERAPEUTIC CORPORATION 5555 VALLEY BOULEVARD LOS ANGELES CA 90032 DD 08/23/95 MA / /
FILGRASTIM TN= NEUPOGEN	FOR USE IN THE MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS FOR COLLECTION IN PATIENTS WHO WILL RECEIVE MYELOABLATIVE OR MYELOSUPPRESSIVE CHEMOTHERAPY.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 07/17/95 MA / /
GABAPENTIN TN= NEURONTIN	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	WARNER-LAMBERT COMPANY PARKE-DAVIS PHARMACEUTICAL RESEARCH DIV. ANN ARBOR MI 48105-2430 DD 07/05/95 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
GLUTAMINE TN=	FOR USE WITH HUMAN GROWTH HORMONE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
GLYCERYL TRIOLEATE AND GLYCERYL TRIERUCATE TN= LORENZO'S OIL	TREATMENT OF ADRENOLEUKODYSTROPHY.	MOSER, HUGO W. M.D. JOHNS HOPKINS UNIVERSITY BALTIMORE MD 21205 DD 02/14/95 MA / /
HEPATITIS B IMMUNE GLOBULIN, INTRAVENOUS TN= H-BIGIV	PROPHYLAXIS AGAINST HEPATITIS B VIRUS REINFECTION IN LIVER TRANSPLANT PATIENTS.	NORTH AMERICAN BIOLOGICS, INC. 16500 N.W. 15th AVENUE MIAMI FL 33169 DD 03/08/95 MA / /
HUMAN GROWTH HORMONE TN=	FOR USE WITH GLUTAMINE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TN= HIVIG	TREATMENT OF HIV-INFECTED PEDIATRIC PATIENTS.	NORTH AMERICAN BIOLOGICALS, INC. 16500 N.W. 15TH AVENUE MIAMI FL 33169 DD 01/04/95 MA / /
INTRAVITREAL GANCICLOVIR FREE ACID IMPLANT TN= VITRASERT IMPLANT	TREATMENT OF CYTOMEGALOVIRUS RETINITIS.	CHIRON VISION 500 IOLAB DRIVE CLAREMONT CA 91711 DD 06/07/95 MA / /
KL4-SURFACTANT TN=	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 07/17/95 MA / /
LAMOTRIGINE TN= LAMICTAL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	BURROUGHS-WELLCOME COMPANY 3030 CORNWALLIS ROAD, P.O. BOX 12700 RESEARCH TRIANGLE PK NC 27709 DD 08/23/95 MA / /
MITOLACTOL TN=	AS ADJUVANT THERAPY IN THE TREATMENT OF PRIMARY BRAIN TUMORS.	BIOPHARMACEUTICS, INC. 990 STATION ROAD BELLPORT NY 11713 DD 07/12/95 MA / /
NITRIC OXIDE TN=	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS.	OHMEDA PHARMACEUTICAL PRODUCTS DIVISION 110 ALLEN ROAD LIBERTY CORNER NJ 07938-0804 DD 07/10/95 MA / /
NTBC TN=	TREATMENT OF TYROSINEMIA TYPE 1.	SWEDISH ORPHAN AB ORPHAN PHARMACEUTICAL, USA, INC. NASHVILLE TN 37217 DD 05/16/95 MA / /
PHENYLALANINE AMMONIA-LYASE TN= PHENYLASE	TREATMENT OF HYPERPHENYLALANINEMIA.	IBEX TECHNOLOGIES, INC. 5485 PARE MONTREAL, QUEBEC DD 03/08/95 MA / /
PURIFIED TYPE II COLLAGEN TN= COLLORAL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	AUTOIMMUNE, INCORPORATED 128 SPRING STREET LEXINGTON MA 02173 DD 02/09/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF ACUTE AND CHRONIC RESPIRATORY SYMPTOMS OF BRONCHIECTASIS.	BIOGEN, INCORPORATED 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 03/06/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF GROWTH HORMONE RECEPTOR DEFICIENCY.	PHARMACIA, INC. PO BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF ANTIBODY-MEDIATED GROWTH HORMONE RESISTANCE IN PATIENTS WITH ISOLATED GROWTH HORMONE DEFICIENCY IA.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT METHIONYL HUMAN STEM CELL FACTOR TN=	FOR USE IN COMBINATION WITH FILGRASTIM TO DECREASE THE NUMBER OF PHERESES REQUIRED TO COLLECT PERIPHERAL BLOOD PROGENITOR CELLS CAPABLE OF PROVIDING RAPID MULTI-LINEAGE HEMATOPOIETIC RECONSTITUTION FOLLOWING MYELOSUPPRESSIVE OR MYELOABLATIVE THERAPY.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 07/05/95 MA / /
RIFAPENTINE TN=	TREATMENT OF PULMONARY TUBERCULOSIS.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 94137 DD 06/09/95 MA / /
RIFAPENTINE TN=	TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 64137 DD 06/09/95 MA / /
SARGRAMOSTIM TN= LEUKINE	TO REDUCE NEUTROPENIA AND LEUKOPENIA AND DECREASE THE INCIDENCE OF DEATH DUE TO INFECTION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA.	IMMUNEX CORPORATION 51 UNIVERSITY STREET SEATTLE WA 98101 DD 03/06/95 MA / /
SU-101 TN=	TREATMENT OF MALIGNANT GLIOMA.	SUGEN, INC. 515 GALVESTON DRIVE REDWOOD CITY CA 94063-4720 DD 05/25/95 MA / /
SYNSORB PK TN=	TREATMENT OF VEROCYTOTOXOGENIC E. COLI INFECTIONS.	SYNSORB BIOTECH INC. FOURTH FLOOR, 140 4TH AVENUE SW CALGARY, ALBERTA DD 07/17/95 MA / /
THALIDOMIDE TN=	TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN SEVERLY, TERMINALLY IMMUNOCOMPROMISED PATIENTS.	CELGENE CORPORATION P.O. BOX 4914 WARREN NJ 07059 DD 05/01/95 MA / /
THALIDOMIDE TN=	TREATMENT AND PREVENTION OF RECURRENT APHTHOUS ULCERS IN SEVERLY, TERMINALLY IMMUNOCPOMPROMISED PATIENTS.	ANDRULIS RESEARCH CORPORATION 11800 BALTIMORE AVENUE, SUITE 113 BELTSVILLE MD 20705 DD 05/15/95 MA / /
THALIDOMIDE TN= SYNOVIR	TREATMENT OF ERYTHEMA NODOSUM LEPROSUM.	CELGENE CORPORATION 7 POWDER HORN DRIVE, PO BOX 4914 WARREN NJ 07059 DD 07/26/95 MA / /
TRISODIUM CITRATE CONCENTRATION TN= HEMOCITRATE	FOR USE IN LEUKAPHERESIS PROCEDURES.	HEMOTEC MEDICAL PRODUCTS, INC. BOX 19255 JOHNSTON RI 02919 DD 06/15/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
TYLOXAPOL TN=	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs 50 NORTH MEDICAL DRIVE, U OF UTAH SALT LAKE CITY UT 84132 DD 03/08/95 MA / /

APPROVED ORPHAN PRODUCTS

AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA 08/03/95
DEXRAZOXANE TN= ZINECARD	FOR THE PREVENTION OF CARDIOMYOPATHY ASSOCIATED WITH DOXORUBICIN ADMINISTRATION.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 12/17/91 MA 05/26/95
Rho (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= WinRho SD	TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA.	RH PHARMACEUTICALS, INC. 104 CHANCELLOR MATHESON ROAD WINNIPEG, MANITOBA DD 11/09/93 MA 03/24/95

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 1995 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
CORTICOSTEROIDS, DERMATOLOGIC *IN VIVO* (TOPICAL)	JUN 02, 1995	
FLURBIPROFEN (TABLET)	DEC 24, 1992	JUN 08, 1995
NAPROXEN (TABLET)	JUN 12, 1992	JUN 08, 1995

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 15MG	94 P-0212/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 30MG	94 P-0211/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 60MG	94 P-0210/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE TABLET; ORAL	712.8MG 60MG 32MG	93 P-0484/ CP1	MIKART	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET, CHEWABLE; ORAL	120MG 12MG	94 P-0182/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ALBUTEROL SULFATE TABLET, CHEWABLE; ORAL	EQ 2MG BASE EQ 4MG BASE	92 P-0335/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ATRACURIUM BESYLATE INJECTABLE; INJECTION	25MG/ML	94 P-0314/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAY 02, 1995
CALCITONIN, SALMON INJECTABLE; INJECTION	100 IU/ML (0.5ML/AMP) 1ML/AMP)	95 P-0080/ CP1	FERRING	NEW STRENGTH	APPROVED AUG 07, 1995
CAPTOPRIL SOLUTION; ORAL	25MG/ML	95 P-0008/ CP1	ROXANE	NEW DOSAGE FORM NEW STRENGTH	APPROVED AUG 07, 1995
IOPAMIDOL INJECTABLE; INJECTION	61% (250ML/CONTAINER) (500ML/CONTAINER)	95 P-0073/ CP1	ABBOTT	NEW STRENGTH	APPROVED AUG 23, 1995
IOPAMIDOL INJECTABLE; INJECTION	76% (250ML/CONTAINER) (500ML/CONTAINER)	95 P-0073/ CP1	ABBOTT	NEW STRENGTH	APPROVED AUG 23, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (5ML/VIAL)	94 P-0433/ CP2	LEDERLE	NEW DOSAGE FORM	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (20ML/VIAL)	94 P-0433/ CP3	LEDERLE	NEW DOSAGE FORM NEW STRENGTH	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (35ML/VIAL)	94 P-0433/ CP1	LEDERLE	NEW DOSAGE FORM	APPROVED AUG 07, 1995

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (100MG/VIAL)	93 P-0427/ CP3	ABBOTT	NEW DOSAGE FORM	APPROVED JAN 19, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (250MG/VIAL)	93 P-0427/ CP2	ABBOTT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
LORAZEPAM SOLUTION; ORAL	0.5MG/5ML	94 P-0199/ CP1	ROXANE	NEW DOSAGE FORM	APPROVED FEB 07, 1995
MEDROXYPROGESTERONE ACETATE TABLET; ORAL	2MG 4MG 8MG	92 P-0452/ CP1	CARNRICK	NEW STRENGTH	APPROVED AUG 07, 1995
METHYLPREDNISOLONE TABLET, CHEWABLE; ORAL	4MG 16MG 24MG 32MG	94 P-0432/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED AUG 07, 1995
SULFAMETHOXAZOLE; TRIMETHOPRIM TABLET, CHEWABLE; ORAL	200MG 40MG	94 P-0186/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
THIORIDAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0283/ CP1	UDL LABS	NEW STRENGTH	APPROVED JAN 19, 1995

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
NICOTINE POLACRILEX LOLLIPOP; ORAL	2MG	93 P-0414/ CP1	SAVAGE	NEW DOSAGE FORM	DENIED MAY 02, 1995
SELEGILINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL	10MG	94 P-0387/ CP1	PHARMAVENE	NEW DOSAGE FORM NEW STRENGTH	DENIED MAY 08, 1995
TERFENADINE TABLET, CHEWABLE; ORAL	60MG	94 P-0119/ CP1	DURA PHARMS	NEW DOSAGE FORM	DENIED AUG 23, 1995

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300

REFERENCES

NEW INDICATION

I-117	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB)
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER

REFERENCES

PATENT USE CODE

U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGICAL HYPERSECRETORY CONDITIONS

EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-109	USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19872 001	ACETAMINOPHEN; TYLENOL	5004613	JUL 27, 2007			
			4968509	NOV 06, 2007			
			4820522	JUL 27, 2007		NDF	JUN 08, 1997
	19806 001	ACRIVASTINE; SEMPREX-D	4501893	FEB 01, 2003			
	20059 001	ADENOSINE; ADENOSCAN				I-126	MAY 18, 1998
	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	4353365	APR 24, 1998			
			4206758	APR 24, 1998			
	18702 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
	18707 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
	20379 001	ALPROSTADIL; CAVERJECT				NP	JUL 06, 1998
	20379 002	ALPROSTADIL; CAVERJECT				NP	JUL 06, 1998
>ADD>	20377 001	AMIODARONE HYDROCHLORIDE; CORDARONE				ODE	AUG 03, 2002
>ADD>						NDF	AUG 03, 1998
	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	20364 002	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
	20364 003	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
	20364 004	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
	20259 001	ATOVAQUONE; MEPRON	4981874	AUG 15, 2009	U-69		
	20500 001	ATOVAQUONE; MEPRON	5053432	OCT 01, 2008		NCE	NOV 25, 1997
			4981874	AUG 15, 2009	U-69	NDF	FEB 08, 1998
	18644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
	18644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
>ADD>	20313 002	CALCITONIN, SALMON; MIACALCIN				NDF	AUG 17, 1998
	18343 001	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 002	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 003	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 005	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 006	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18709 001	CAPTOPRIL; CAPOZIDE 25/15	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 002	CAPTOPRIL; CAPOZIDE 25/25	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 003	CAPTOPRIL; CAPOZIDE 50/25	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 004	CAPTOPRIL; CAPOZIDE 50/15	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	19856 001	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
			4832957	JUN 16, 2006			
	19856 002	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
			4832957	JUN 16, 2006			
	20044 001	CETYL ALCOHOL; EXOSURF NEONATAL	5110806	MAY 02, 2006			
			4312860	NOV 21, 2001			
	18663 001	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
	18663 002	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
	20238 001	CIMETIDINE; TAGAMET HB				NS	JUN 19, 1998
	18891 001	CLONIDINE; CATAPRES-TTS-1	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18891 002	CLONIDINE; CATAPRES-TTS-2	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	18891 003	CLONIDINE; CATAPRES-TTS-3	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	20222 001	COLESTIPOL HYDROCHLORIDE; COLESTID				NDF	JUL 19, 1997
	12142 006	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 007	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 008	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 009	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 010	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	20287 001	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2000		NCE	DEC 22, 1999
	19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4252721	FEB 07, 2003			
	20212 001	DEXRAZOXANE HYDROCHLORIDE; ZINECARD				NCE	MAY 26, 2000
						ODE	MAY 26, 2002
	20212 002	DEXRAZOXANE HYDROCHLORIDE; ZINECARD				NCE	MAY 26, 2000
						ODE	MAY 26, 2002
	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	MAY 20, 2011			
	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	MAY 20, 2011			
	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	MAY 20, 2011			
	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	MAY 20, 2011			
>ADD>	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
>DLT>						~~I-120~~	~~OCT 15, 1995~~
>ADD>	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
>DLT>						~~I-120~~	~~OCT 15, 1995~~
>ADD>	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
>DLT>						~~I-120~~	~~OCT 15, 1995~~
	20411 001	DINOPROSTONE; CERVIDIL	5269321	DEC 14, 2010	U-110		
			4931288	JAN 16, 2007		NDF	MAR 30, 1998
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
	20408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413	JUN 30, 2004	U-103	NCE	DEC 09, 1999
			4619939	OCT 28, 2003	U-104		
	19946 001	DOXACURIUM CHLORIDE; NUROMAX				I-121	DEC 08, 1997
	19668 001	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	19668 002	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	19668 003	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19668 004	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
20126 001	DOXEPIN HYDROCHLORIDE; ZONALON	4395420	DEC 09, 2001	U-95		
19221 003	ENALAPRIL MALEATE; VASERETIC	4472380	SEP 18, 2001			
		4374829	FEB 22, 2000		NS	JUL 12, 1998
19616 004	ENOXACIN; PENETREX	4442101	FEB 04, 2002			
19616 005	ENOXACIN; PENETREX	4442101	FEB 04, 2002			
20164 001	ENOXAPARIN SODIUM; LOVENOX				I-118	MAR 09, 1998
18418 001	ERGOLOID MESYLATES; HYDERGINE	4138565	MAY 26, 1996			
18706 001	ERGOLOID MESYLATES; HYDERGINE LC	4366145	JUN 24, 2001			
19081 002	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
19081 003	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
20323 001	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20323 002	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20323 003	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20323 004	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20375 001	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
20375 002	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
86069 001	ESTRADIOL; ESTRACE	4436738	MAR 15, 2002			
20303 001	ESTROGENS, CONJUGATED; PREMPRO (PREMARIN;CYCRIN 14/14)	4826831	MAY 02, 2006	U-102	NP	DEC 30, 1997
18977 001	ETHINYL ESTRADIOL; TRI-NORINYL 21-DAY	4390531	AUG 10, 2001			
18977 002	ETHINYL ESTRADIOL; TRI-NORINYL 28-DAY	4390531	AUG 10, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18985 001	ETHINYL ESTRADIOL; ORTHO-NOVUM 7/7/7-21	4628051	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4530839	SEP 26, 2003			
18985 002	ETHINYL ESTRADIOL; ORTHO-NOVUM 7/7/7-28	4628051	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4530839	SEP 26, 2003			
19697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
19697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003			
		4544554	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
20325 001	FAMOTIDINE; PEPCID AC	4283408	AUG 11, 2000		NS	APR 28, 1998
20189 001	FELBAMATE; FELBATOL	5082861	DEC 07, 2010	U-83		
		4978680	SEP 26, 2009	U-83		
20189 002	FELBAMATE; FELBATOL	5082861	DEC 07, 2010	U-83		
		4978680	SEP 26, 2009	U-83		
20189 003	FELBAMATE; FELBATOL	5082861	DEC 07, 2010	U-83		
		4978680	SEP 26, 2009	U-83		
19834 001	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
		4264611	APR 28, 2000	U-3	NCE	JUL 25, 1996
>ADD>						
>DLT>		~~4264611~~	~~APR 28, 1998~~			
19834 002	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
		4264611	APR 28, 2000	U-3	NCE	JUL 25, 1996
>ADD>						
>DLT>		~~4264611~~	~~APR 28, 1998~~			
19834 004	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
		4264611	APR 28, 2000	U-3	NCE	JUL 25, 1996
>ADD>						
>DLT>		~~4264611~~	~~APR 28, 1998~~			
19813 001	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 002	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 003	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 004	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19960 001	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 002	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 003	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 004	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19949 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
19949 002	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
19949 003	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
19950 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
20090 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
20090 002	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
20322 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
20073 001	FLUMAZENIL; ROMAZICON	4316839	MAR 02, 2003			
18148 001	FLUNISOLIDE; NASALIDE	4933168	JUN 12, 2007			
18340 001	FLUNISOLIDE; AEROBID	4933168	JUN 12, 2007			
20409 001	FLUNISOLIDE; NASAREL	4983595	MAY 22, 2006			
		4933168	JUN 12, 2007			
		4782047	MAY 22, 2006			
19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				I-122	FEB 16, 1998
19957 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 15, 2002			
19958 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 15, 2002			
20121 001	FLUTICASONE PROPIONATE; FLONASE	4335121	MAR 15, 2002		NCE	DEC 14, 1995
					NDF	OCT 19, 1997
20261 001	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
20261 002	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
20068 001	FOSCARNET SODIUM; FOSCAVIR	4339445	JUL 29, 1997	U-64	I-127	JUN 16, 1998
19915 002	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
		4384123	DEC 04, 2000		I-92	MAY 02, 1998
19915 003	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
		4384123	DEC 04, 2000		I-92	MAY 02, 1998
19915 004	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
		4384123	DEC 04, 2000		I-92	MAY 02, 1998
		4337201	JUN 29, 2001		NCE	MAY 16, 1996
20286 001	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
		4384123	DEC 04, 2000			
20286 002	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
		4384123	DEC 04, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20235 001	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
20235 002	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
20235 003	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	5362475	NOV 08, 2011			
20460 001	GANCICLOVIR; CYTOVENE	4507305	OCT 19, 1999	U-64	NDF	DEC 22, 1997
		4355032	MAR 16, 2003	U-64		
19661 001	GANCICLOVIR SODIUM; CYTOVENE	4507305	MAY 21, 2001	U-35		
		4423050	MAY 21, 2001	U-34		
20329 001	GLIPIZIDE; GLUCOTROL XL	5091190	JUN 18, 2008	U-111		
		5082668	SEP 16, 2003			
		5024843	SEP 05, 2009			
		4612008	SEP 16, 2003			
		4327725	NOV 25, 2000		NDF	APR 26, 1997
20329 002	GLIPIZIDE; GLUCOTROL XL	5091190	JUN 18, 2008	U-111		
		5082668	SEP 16, 2003			
		5024843	SEP 05, 2009			
		4612008	SEP 16, 2003			
		4327725	NOV 25, 2000		NDF	APR 26, 1997
20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 12, 2006	U-105	NCE	DEC 29, 1998
					NDF	MAR 16, 1998
19059 001	HYDROCHLOROTHIAZIDE; INDERIDE LA 80/50	4138475	SEP 14, 1997			
19059 002	HYDROCHLOROTHIAZIDE; INDERIDE LA 120/50	4138475	SEP 14, 1997			
19059 003	HYDROCHLOROTHIAZIDE; INDERIDE LA 160/50	4138475	SEP 14, 1997			
19129 001	HYDROCHLOROTHIAZIDE; MAXZIDE	4444769	JUL 27, 2002			
19129 003	HYDROCHLOROTHIAZIDE; MAXZIDE-25	4444769	JUL 27, 2002			
20387 001	HYDROCHLOROTHIAZIDE; HYZAAR	5153197	OCT 06, 2009	U-3	NC	APR 28, 1998
		5138069	AUG 11, 2009		NCE	APR 14, 2000
19842 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		I-123	MAR 24, 1998
20135 001	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
		5215755	JUN 01, 2010		NDF	NOV 16, 1997
20135 002	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
		5215755	JUN 01, 2010		NDF	NOV 16, 1997
20418 001	IBUPROFEN; MOTRIN				I-123	MAR 24, 1998
20516 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
18185 001	INDOMETHACIN; INDOCIN SR	4173626	DEC 11, 1998			
20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131				ODE	MAR 25, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18956 007	IOHEXOL; OMNIPAQUE 70	4396597	JUL 14, 1998			
			4250113	DEC 26, 1999			
	18735 004	IOPAMIDOL; ISOVUE-M 300	4001323	JAN 04, 1996		D-28	MAY 15, 1998
>ADD>	20220 001	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
>ADD>	20220 002	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
>ADD>	20220 003	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
>ADD>	20220 004	IOPROMIDE; ULTRAVIST	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
	19710 005	IOVERSOL; OPTIRAY 350				I-131	JUN 21, 1998
	20225 003	ISOSORBIDE MONONITRATE; IMDUR				NDF	AUG 12, 1996
						NCE	DEC 30, 1996
	20336 001	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
	20336 002	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
	19816 002	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	19816 003	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
	19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4454151	MAR 22, 2002	U-75		
	18686 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4328213	NOV 28, 1999			
	20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20406 001	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
			5045321	SEP 03, 2008			
			5026560	JUN 25, 2008			
			4689333	JUL 29, 2005			
			4628098	JUL 29, 2005		NCE	MAY 10, 2000
	20406 002	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
			5045321	SEP 03, 2008			
			5026560	JUN 25, 2008			
			4689333	JUL 29, 2005			
			4628098	JUL 29, 2005		NCE	MAY 10, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
		4005063	JAN 25, 1996		I-119	MAR 30, 1998
20263 001	LEUPROLIDE ACETATE; LUPRON	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
20263 005	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20263 006	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4677191	JUL 03, 2005			
		4652441	NOV 01, 2004			
		4264573	MAY 21, 1999			
18027 001	LITHIUM CARBONATE; LITHOBID	4282233	AUG 04, 2000		NCE	APR 12, 1998
19670 001	LORATADINE; CLARITIN-D	5153197	OCT 06, 2009	U-3		
20386 001	LOSARTAN POTASSIUM; COZAAR	5138069	AUG 11, 2009		NCE	APR 14, 2000
20386 002	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009		NCE	APR 14, 2000
19643 002	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998
19643 003	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998
19643 004	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998
19940 001	MASOPROCOL; ACTINEX	4695590	SEP 04, 2006		NCE	SEP 04, 1997
19591 001	MEFLOQUINE HYDROCHLORIDE; LARIAM	4579855	OCT 01, 2004			
20207 001	MELPHALAN HYDROCHLORIDE; ALKERAN	4997651	NOV 18, 2008			
18029 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN-SR	4137300	AUG 20, 1996			
19962 001	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
19962 002	METOPROLOL SUCCINATE; TOPROL-XL	4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
		5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
19962 003	METOPROLOL SUCCINATE; TOPROL-XL	4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
		5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
18654 001	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
18654 002	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
19268 001	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
19268 003	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	MAY 24, 2007		NCE	APR 19, 2000
20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	MAY 24, 2007		NCE	APR 19, 2000
20459 001	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
20459 002	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
18932 001	NALTREXONE HYDROCHLORIDE; REVIA	4338317	MAR 16, 2001		I-129	DEC 30, 1997
20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	5164405	NOV 17, 2009			
		4880823	NOV 14, 2006			
20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
20076 001	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
20076 002	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
20076 003	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
20150 001	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
20150 002	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
20150 003	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
20165 001	NICOTINE; NICODERM	5364630	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5004610	JUN 14, 2008			
20165 002	NICOTINE; NICODERM	5364630	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5004610	JUN 14, 2008			
20165 003	NICOTINE; NICODERM	5364630	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5004610	JUN 14, 2008			
19684 001	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
19684 002	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
19684 003	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
20198 001	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20198 002	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			
20198 003	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			
20356 001	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 002	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 003	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 004	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20064 001	NITROFURANTOIN; MACROBID	4798725	JUN 16, 2006			
		4772473	JUN 16, 2006			
20145 001	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 002	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 003	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 004	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 005	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 006	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
19508 001	NIZATIDINE; AXID	4375547	APR 12, 2002			
19508 002	NIZATIDINE; AXID	4375547	APR 12, 2002			
19384 002	NORFLOXACIN; NOROXIN	4639458	JAN 22, 2005			
19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 14, 2003			
20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
20087 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
20087 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
19810 001	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108		
		4786505	APR 20, 2007	U-108	I-130	JUN 22, 1998
20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4255431	MAR 10, 2000	U-108		
		4753789	JUN 24, 2006	U-44		
20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 25, 2005		D-20	FEB 02, 1996
		4753789	JUN 24, 2006	U-44	D-27	APR 10, 1998
		4695578	JAN 25, 2005		NCE	JAN 04, 1996
					I-9	APR 19, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-27	APR 10, 1998
		4695578	JAN 25, 2005		NCE	JAN 04, 1996
					I-9	APR 19, 1998
20403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-20	FEB 02, 1996
		4695578	JAN 25, 2005		NCE	JAN 04, 1996
					I-9	AUG 13, 1996
19828 001	OXICONAZOLE NITRATE; OXISTAT	4124767	DEC 27, 1996			
20209 001	OXICONAZOLE NITRATE; OXISTAT	4124767	DEC 27, 1996			
20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005			
20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005			
20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005			
19385 001	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
		4166182	FEB 08, 2000			
19385 002	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
		4166182	FEB 08, 2000			
19385 003	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
		4166182	FEB 08, 2000			
17850 001	POTASSIUM CHLORIDE; KLOTRIX	4140756	JUN 10, 1996			
18238 001	POTASSIUM CHLORIDE; MICRO-K	4259315	JUN 13, 2000			
18238 002	POTASSIUM CHLORIDE; MICRO-K 10	4259315	JUN 13, 2000			
19561 003	POTASSIUM CHLORIDE; MICRO-K LS	4259315	JUN 13, 2000			
19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4327725	NOV 25, 2000			
19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4327725	NOV 25, 2000			
18553 001	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
18553 002	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
18553 003	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
18553 004	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
19536 001	PROPRANOLOL HYDROCHLORIDE; INDERAL	4600708	JUL 19, 2005			
19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4929605	OCT 07, 2007	U-81		
		4254129	APR 10, 1999	U-81		
20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAR 14, 2006			
19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		4344949	AUG 17, 2001	U-3		
19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		4344949	AUG 17, 2001	U-3		
19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		4344949	AUG 17, 2001	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
>ADD>	19901 001	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
>ADD>	19901 002	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
>ADD>	19901 003	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
>ADD>	19901 004	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4880636	MAY 13, 2008			
			4128658	JUL 25, 1997		I-120	MAR 29, 1998
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4880636	MAY 13, 2008			
			4128658	JUL 25, 1997		I-120	MAR 29, 1998
	19090 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4128658	JUL 25, 1997			
	19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	JUL 25, 1997			
	19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	JUL 25, 1997			
	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	FEB 22, 2010		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	FEB 22, 2010		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	APR 13, 2008			
	20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	APR 13, 2008			
	20236 001	SALMETEROL XINAFOATE; SEREVENT	5380922	MAY 14, 2013			
	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	20478 001	SEVOFLURANE; ULTANE				NCE	JUN 07, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19766 001	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 002	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 003	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 004	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		
	20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		
	20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		
	20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		
>ADD>	19829 001	TECHNETIUM TC-99M EXAMETAZIME KIT; CERETEC	4789736	DEC 06, 2005		I-124	APR 07, 1998
			4615876	MAR 14, 2008			
	19981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG	4755375	APR 17, 2008	U-51		
	19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
			4112097	JAN 21, 1997	U-3		
	19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			4112097	JAN 21, 1997	U-3		
	19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
			4112097	JAN 21, 1997	U-3		
	19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
			4112097	JAN 21, 1997	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
			APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
18949 001	TERFENADINE; SELDANE	4254129	APR 10, 1999	U-81		
19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
20439 001	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
20439 002	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
20136 001	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
20136 002	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
20136 003	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
20136 004	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
20137 002	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
20281 001	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
20281 002	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
		4215104	MAR 26, 1999			
18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
		4215104	MAR 26, 1999			
19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	4767612	JAN 23, 2007	U-85		
20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	MAY 20, 2006	U-91		
		4376858	OCT 31, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	SEP 18, 2007		NE	JUN 23, 1998
20487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	SEP 18, 2007		NE	JUN 23, 1998
18776 002	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
		4237126	AUG 20, 1999			
18776 003	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
		4237126	AUG 20, 1999			
20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
19614 001	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
19614 002	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
20388 001	VINORELBINE TARTRATE; NAVELBINE	4307100	NOV 23, 2001		NCE	DEC 23, 1999
19655 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
19910 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
19951 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			

*U.S. Government Printing Office: 1995 - 404-907/20002

New 15th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7542

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $64.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/94)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 512-1800.